Influenza vaccine explained

Type:vaccine
Target:Influenza virus
Vaccine Type:inactivated, attenuated, recombinant
Tradename:Afluria, Fluarix, Fluzone, others
Drugs.Com:Inactivated: Intranasal: Recombinant:
Pregnancy Au:B1
Pregnancy Au Comment:or B2 (depending on vaccine brand)[1] [2] [3]
Routes Of Administration:Intramuscular, intranasal, intradermal
Atc Prefix:J07
Atc Suffix:BB01
Atc Supplemental:,,
Legal Au:S4
Legal Au Comment:[4] [5] [6]
Legal Ca:Rx-only
Legal Ca Comment:/ Schedule D[7] [8] [9] [10] [11]
Legal Uk:POM
Legal Us:Rx-only
Legal Eu:Rx-only
Legal Eu Comment:[12] [13]
Legal Status:Rx-only
Cas Number:1704512-59-3
Chemspiderid:none
Kegg:D04536

Influenza vaccines, colloquially known as flu shots, are vaccines that protect against infection by influenza viruses.[14] [15] New versions of the vaccines are developed twice a year, as the influenza virus rapidly changes.[14] While their effectiveness varies from year to year, most provide modest to high protection against influenza.[14] [16] Vaccination against influenza began in the 1930s, with large-scale availability in the United States beginning in 1945.[17] [18]

Both the World Health Organization and the US Centers for Disease Control and Prevention (CDC) recommend yearly vaccination for nearly all people over the age of six months, especially those at high risk,[19] [20] and the influenza vaccine is now on the WHO's List of Essential Medicines.[21] [22] The European Centre for Disease Prevention and Control (ECDC) also recommends yearly vaccination of high-risk groups,[23] particularly pregnant women, the elderly, children between six months and five years, and those with certain health problems.

The vaccines are generally safe, including for people who have severe egg allergies.[24] A common side effect is soreness near the site of injection. Fever occurs in five to ten percent of children vaccinated, and temporary muscle pains or feelings of tiredness may occur. In certain years, the vaccine was linked to an increase in Guillain–Barré syndrome among older people at a rate of about one case per million doses. Influenza vaccines are not recommended in those who have had a severe allergy to previous versions of the vaccine itself. The vaccine comes in inactive and weakened viral forms. The live, weakened vaccine is generally not recommended in pregnant women, children less than two years old, adults older than 50, or people with a weakened immune system.[14] Depending on the type it can be injected into a muscle, sprayed into the nose, or injected into the middle layer of the skin (intradermal).[14] The intradermal vaccine was not available during the 2018–2019 and 2019–2020 influenza seasons.[25] [26] [27]

History

See also: Timeline of vaccines.

Vaccines are used in both humans and non-humans. Human vaccine is meant unless specifically identified as a veterinary, poultry or livestock vaccine.

Origins and development

During the worldwide Spanish flu pandemic of 1918, "Pharmacists tried everything they knew, everything they had ever heard of, from the ancient art of bleeding patients, to administering oxygen, to developing new vaccines and serums (chiefly against what we now call Hemophilus influenzaea name derived from the fact that it was originally considered the etiological agentand several types of pneumococci). Only one therapeutic measure, transfusing blood from recovered patients to new victims, showed any hint of success."[28]

In 1931, viral growth in embryonated hens' eggs was reported by Ernest William Goodpasture and colleagues at Vanderbilt University. The work was extended to growth of influenza virus by several workers, including Thomas Francis, Jonas Salk, Wilson Smith, and Macfarlane Burnet, leading to the first experimental influenza vaccines.[29] In the 1940s, the US military developed the first approved inactivated vaccines for influenza, which were used during World War II.[30] Hens' eggs continued to be used to produce virus used in influenza vaccines, but manufacturers made improvements in the purity of the virus by developing improved processes to remove egg proteins and to reduce systemic reactivity of the vaccine.[31] In 2012, the US Food and Drug Administration (FDA) approved influenza vaccines made by growing virus in cell cultures[32] [33] and influenza vaccines made from recombinant proteins[34] have been approved, with plant-based influenza vaccines being tested in clinical trials.[35]

Acceptance

The egg-based technology for producing influenza vaccine was created in the 1950s.[36] In the US swine flu scare of 1976, President Gerald Ford was confronted with a potential swine flu pandemic. The vaccination program was rushed, yet plagued by delays and public relations problems. Meanwhile, maximum military containment efforts succeeded unexpectedly in confining the new strain to the single army base where it had originated. On that base, a number of soldiers fell severely ill, but only one died. The program was canceled after about 24% of the population had received vaccinations. An excess in deaths of 25 over normal annual levels as well as 400 excess hospitalizations, both from Guillain–Barré syndrome, were estimated to have occurred from the vaccination program itself, demonstrating that the vaccine itself is not free of risks.[37] In the end, however, even the maligned 1976 vaccine may have saved lives. A 2010 study found a significantly enhanced immune response against the 2009 pandemic H1N1 in study participants who had received vaccination against the swine flu in 1976.[38] The 2009 H1N1 "swine flu" outbreak resulted in the rapid approval of pandemic influenza vaccines.[39] Pandemrix was quickly modified to target the circulating strain and by late 2010, 70 million people had received a dose.[40] Eight years later, the BMJ gained access to vaccine pharmacovigilance reports compiled by GSK (GlaxoSmithKline) during the pandemic which the BMJ reported indicated death was 5.39 fold more likely with Pandemrix vs the other pandemic vaccines.

Quadrivalent vaccines

A quadrivalent flu vaccine administered by nasal mist was approved by the FDA in March 2012.[41] [42] Fluarix Quadrivalent was approved by the FDA in December 2012.[43]

In 2014, the Canadian National Advisory Committee on Immunization (NACI) published a review of quadrivalent influenza vaccines.[44]

Starting with the 2018–2019 influenza season most of the regular-dose egg-based flu shots and all the recombinant and cell-grown flu vaccines in the United States are quadrivalent.[45] In the 2019–2020 influenza season all regular-dose flu shots and all recombinant influenza vaccine in the United States are quadrivalent.

In November 2019, the FDA approved Fluzone High-Dose Quadrivalent for use in the United States starting with the 2020–2021 influenza season.[46] [47]

In February 2020, the FDA approved Fluad Quadrivalent for use in the United States.[48] In July 2020, the FDA approved both Fluad and Fluad Quadrivalent for use in the United States for the 2020–2021 influenza season.[49]

The B/Yamagata lineage of influenza B, one of the four lineages targeted by quadrivalent vaccines, might have become extinct in 2020/2021 due to COVID-19 pandemic measures,[50] and there have been no naturally occurring cases confirmed since March 2020. In 2023, the World Health Organization concluded that protection against the Yamagata lineage was no longer necessary in the seasonal flu vaccine, so future vaccines are recommended to be trivalent instead of quadrivalent.[51] [52] For the 2024–2025 Northern Hemisphere influenza season, the FDA recommends removing B/Yamagata from all influenza vaccines.

Medical uses

The US Centers for Disease Control and Prevention (CDC) recommends the flu vaccine as the best way to protect people against the flu and prevent its spread. The flu vaccine can also reduce the severity of the flu if a person contracts a strain that the vaccine did not contain.[53] It takes about two weeks following vaccination for protective antibodies to form.

A 2012 meta-analysis found that flu vaccination was effective 67percent of the time; the populations that benefited the most were HIV-positive adults aged 18 to 55 (76percent), healthy adults aged 18 to 46 (approximately 70percent), and healthy children aged six months to 24 months (66percent).[54] The influenza vaccine also appears to protect against myocardial infarction with a benefit of 15–45%.[55]

Effectiveness

A vaccine is assessed by its efficacy – the extent to which it reduces risk of disease under controlled conditions – and its effectiveness – the observed reduction in risk after the vaccine is put into use.[56] In the case of influenza, effectiveness is expected to be lower than the efficacy because it is measured using the rates of influenza-like illness, which is not always caused by influenza.[57] Studies on the effectiveness of flu vaccines in the real world are difficult; vaccines may be imperfectly matched, virus prevalence varies widely between years, and influenza is often confused with other influenza-like illnesses.[58] However, in most years (16 of the 19 years before 2007), the flu vaccine strains have been a good match for the circulating strains,[59] and even a mismatched vaccine can often provide cross-protection.[53] The virus rapidly changes due to antigenic drift, a slight mutation in the virus that causes a new strain to arise.[60]

The effectiveness of seasonal flu vaccines varies significantly, with an estimated average efficacy of 50–60% against symptomatic disease,[61] depending on vaccine strain, age, prior immunity, and immune function, so vaccinated people can still contract influenza.[62] The effectiveness of flu vaccines is considered to be suboptimal, particularly among the elderly,[63] but vaccination is still beneficial in reducing the mortality rate and hospitalization rate due to influenza as well as duration of hospitalization.[62] [64] Vaccination of school-age children has shown to provide indirect protection for other age groups. LAIVs are recommended for children based on superior efficacy, especially for children under 6, and greater immunity against non-vaccine strains when compared to inactivated vaccines.[65] [66]

From 2012 to 2015 in New Zealand, vaccine effectiveness against admission to an intensive care unit was 82%.[67] Effectiveness against hospitalized influenza illness in the 2019–2020 United States flu season was 41% overall and 54% in people aged 65 years or older.[68] One review found 31% effectiveness against death among adults.[69]

Repeated annual influenza vaccination generally offers consistent year-on-year protection against influenza. There is, however, suggestive evidence that repeated vaccinations may cause a reduction in vaccine effectiveness for certain influenza subtypes; this has no relevance to current recommendations for yearly vaccinations but might influence future vaccination policy.[70] [71], the CDC recommends a yearly vaccine as most studies demonstrate overall effectiveness of annual influenza vaccination.[72]

There is not enough evidence to establish significant differences in the effectiveness of different influenza vaccine types,[73] but there are high-dose or adjuvanted products that induce a stronger immune response in the elderly.[74]

According to a 2016 study by faculty at the University of New South Wales, getting a flu shot was as effective or better at preventing a heart attack than even quitting smoking.[75]

Children

In April 2002, the Advisory Committee on Immunization Practices (ACIP) encouraged that children 6 to 23 months of age be vaccinated annually against influenza.[76] In 2010, ACIP recommended annual influenza vaccination for those 6 months of age and older.[76] Currently the CDC recommends that everyone except infants under the age of six months should receive the seasonal influenza vaccine.[19] Vaccination campaigns usually focus special attention on people who are at high risk of serious complications if they catch the flu, such as pregnant women, children under 59 months, the elderly, and people with chronic illnesses or weakened immune systems, as well as those to whom they are exposed, such as health care workers.[19] [77]

As the death rate is also high among infants who catch influenza, the CDC and the WHO recommend that household contacts and caregivers of infants be vaccinated to reduce the risk of passing an influenza infection to the infant.[78]

In children, the vaccine appears to decrease the risk of influenza and possibly influenza-like illness.[79] In children under the age of two data are limited.[79] During the 2017–18 flu season, the CDC director indicated that 85 percent of the children who died "likely will not have been vaccinated".[80]

In the United States,, the CDC recommend that children aged six through 35 months may receive either 0.25milliliters or 0.5milliliters per dose of Fluzone Quadrivalent.[81] [82] There is no preference for one or the other dose volume of Fluzone Quadrivalent for that age group. All persons 36 months of age and older should receive 0.5 milliliters per dose of Fluzone Quadrivalent., Afluria Quadrivalent is licensed for children six months of age and older in the United States.[83] Children six months through 35 months of age should receive 0.25milliliters for each dose of Afluria Quadrivalent. All persons 36 months of age and older should receive 0.5milliliters per dose of Afluria Quadrivalent., Afluria Tetra is licensed for adults and children five years of age and older in Canada.[84]

In 2014, the Canadian National Advisory Committee on Immunization (NACI) published a review of influenza vaccination in healthy 5–18-year-olds,[85] and in 2015, published a review of the use of pediatric Fluad in children 6–72 months of age.[86] In one study, conducted in a tertiary referral center, the rate of influenza vaccination in children was only 31%. Higher rates were found among immuno-suppressed pediatric patients (46%), and in patients with inflammatory bowel disease (50%).[87]

Adults

In unvaccinated adults, 16% get symptoms similar to the flu, while about 10% of vaccinated adults do. Vaccination decreased confirmed cases of influenza from about 2.4% to 1.1%. No effect on hospitalization was found.

In working adults, a review by the Cochrane Collaboration found that vaccination resulted in a modest decrease in both influenza symptoms and working days lost, without affecting transmission or influenza-related complications. In healthy working adults, influenza vaccines can provide moderate protection against virologically confirmed influenza, though such protection is greatly reduced or absent in some seasons.[88]

In health care workers, a 2006 review found a net benefit.[89] Of the eighteen studies in this review, only two also assessed the relationship of patient mortality relative to staff influenza vaccine uptake; both found that higher rates of health care worker vaccination correlated with reduced patient deaths. A 2014 review found benefits to patients when health care workers were immunized, as supported by moderate evidence[90] based in part on the observed reduction in all-cause deaths in patients whose health care workers were given immunization compared with comparison patients where the workers were not offered vaccine.[91]

Elderly

Evidence for an effect in adults over 65 is unclear.[92] Systematic reviews examining both randomized controlled and case–control studies found a lack of high-quality evidence.[88] [93] Reviews of case–control studies found effects against laboratory-confirmed influenza, pneumonia, and death among the community-dwelling elderly.[94] [95]

The group most vulnerable to non-pandemic flu, the elderly, benefits least from the vaccine. There are multiple reasons behind this steep decline in vaccine efficacy, the most common of which are the declining immunological function and frailty associated with advanced age.[96] In a non-pandemic year, a person in the United States aged 50–64 is nearly ten times more likely to die an influenza-associated death than a younger person, and a person over 65 is more than ten times more likely to die an influenza-associated death than the 50–64 age group.[97]

There is a high-dose flu vaccine specifically formulated to provide a stronger immune response.[98] Available evidence indicates that vaccinating the elderly with the high-dose vaccine leads to a stronger immune response against influenza than the regular-dose vaccine.[99] [100] [101]

A flu vaccine containing an adjuvant was approved by the US Food and Drug Administration (FDA) in November 2015, for use by adults aged 65 years of age and older. The vaccine is marketed as Fluad in the US and was first available in the 2016–2017 flu season. The vaccine contains the MF59C.1 adjuvant[102] which is an oil-in-water emulsion of squalene oil. It is the first adjuvanted seasonal flu vaccine marketed in the United States.[103] [104] It is not clear if there is a significant benefit for the elderly to use a flu vaccine containing the MF59C.1 adjuvant.[105] [106] [107] Per Advisory Committee on Immunization Practices guidelines, Fluad can be used as an alternative to other influenza vaccines approved for people 65 years and older.[108]

Vaccinating health care workers who work with elderly people is recommended in many countries, with the goal of reducing influenza outbreaks in this vulnerable population.[109] [110] [111] While there is no conclusive evidence from randomized clinical trials that vaccinating health care workers helps protect elderly people from influenza, there is tentative evidence of benefit.[112]

Fluad Quad was approved for use in Australia in September 2019,[113] Fluad Quadrivalent was approved for use in the United States in February 2020,[114] and Fluad Tetra was approved for use in the European Union in May 2020.[115] [116]

Pregnancy

As well as protecting mother and child from the effects of an influenza infection, the immunization of pregnant women tends to increase their chances of experiencing a successful full-term pregnancy.[117]

The trivalent inactivated influenza vaccine is protective in pregnant women infected with HIV.[118]

Safety

See also: Vaccine controversies.

Side effects

Common side effects of vaccination include local injection-site reactions and cold-like symptoms. Fever, malaise, and myalgia are less common. Flu vaccines are contraindicated for people who have experienced a severe allergic reaction in response to a flu vaccine or to any component of the vaccine. LAIVs are not given to children or adolescents with severe immunodeficiency or to those who are using salicylate treatments because of the risk of developing Reye syndrome.[65] LAIVs are also not recommended for children under the age of 2,[66] pregnant women, and adults with immunosuppression. Inactivated flu vaccines cannot cause influenza and are regarded as safe during pregnancy.[65]

While side effects of the flu vaccine may occur, they are usually minor, including soreness, redness, and swelling around the point of injection, headache, fever, nausea or fatigue.[119] Side effects of a nasal spray vaccine may include runny nose, wheezing, sore throat, cough, or vomiting.[120]

In some people, a flu vaccine may cause serious side effects, including an allergic reaction, but this is rare. Furthermore, the common side effects and risks are mild and temporary when compared to the risks and severe health effects of the annual influenza epidemic.

Contrary to a common misconception, flu shots cannot cause people to get the flu.[121] [122]

Guillain–Barré syndrome

Although Guillain–Barré syndrome had been feared as a complication of vaccination, the CDC states that most studies on modern influenza vaccines have seen no link with Guillain–Barré.[123] [124] Infection with influenza virus itself increases both the risk of death (up to one in ten thousand) and the risk of developing Guillain–Barré syndrome to a far higher level than the highest level of suspected vaccine involvement (approximately ten times higher by 2009 estimates).[125] [126]

Although one review gives an incidence of about one case of Guillain–Barré per million vaccinations,[127] a large study in China, covering close to a hundred million doses of vaccine against the 2009 H1N1 "swine" flu found only eleven cases of Guillain–Barré syndrome, (0.1 per million doses) total incidence in persons vaccinated, actually lower than the normal rate of the disease in China, and no other notable side effects.[126] [128]

Egg allergy

Although most influenza vaccines are produced using egg-based techniques, influenza vaccines are nonetheless still recommended as safe for people with egg allergies, even if severe,[24] as no increased risk of allergic reaction to the egg-based vaccines has been shown for people with egg allergies.[129] Studies examining the safety of influenza vaccines in people with severe egg allergies found that anaphylaxis was very rare, occurring in 1.3 cases per million doses given.[24]

Monitoring for symptoms from vaccination is recommended in those with more severe symptoms.[130] A study of nearly 800 children with egg allergy, including over 250 with previous anaphylactic reactions, had zero systemic allergic reactions when given the live attenuated flu vaccine.[131] [132]

Vaccines produced using other technologies, notably recombinant vaccines and those based on cell culture rather than egg protein, started to become available from 2012 in the US, and later in Europe and Australia.

Other

Several studies have identified an increased incidence of narcolepsy among recipients of the pandemic H1N1 influenza AS03-adjuvanted vaccine;[133] efforts to identify a mechanism for this suggest that narcolepsy is autoimmune, and that the AS03-adjuvanted H1N1 vaccine may mimic hypocretin, serving as a trigger.[134]

Some injection-based flu vaccines intended for adults in the United States contain thiomersal (also known as thimerosal), a mercury-based preservative.[135] [136] Despite some controversy in the media,[137] the World Health Organization's Global Advisory Committee on Vaccine Safety has concluded that there is no evidence of toxicity from thiomersal in vaccines and no reason on grounds of safety to change to more-expensive single-dose administration.[138]

Types

See main article: List of seasonal influenza vaccines.

Seasonal flu vaccines are available either as:

Injected vaccines induce protection based on an immune response to the antigens present on the inactivated virus, while the nasal spray works by establishing short-term infection in the nasal passages.

Annual reformulation

See also: 2009 flu pandemic vaccine.

Each year, three influenza strains are chosen for inclusion in the fothcoming year's seasonal flu vaccination by the Global Influenza Surveillance and Response System of the World Health Organization (WHO).[140] The recommendation for trivalent vaccine comprises two strains of Influenza A (one each of A/H1N1 and A/H3N2), and one strain of influenza B (B/Victoria), together representing strains thought most likely to cause significant human suffering in the coming season. Starting in 2012, WHO has also recommended a second influenza B strain (B/Yamagata) for use in quadrivalent vaccines; this was discontinued in 2024.

"The WHO Global Influenza Surveillance Network was established in 1952 (renamed "Global Influenza Surveillance and Response System" in 2011).[141] The network comprises four WHO Collaborating Centres (WHO CCs) and 112 institutions in 83 countries, which are recognized by WHO as WHO National Influenza Centres (NICs). These NICs collect specimens in their country, perform primary virus isolation and preliminary antigenic characterization. They ship newly isolated strains to WHO CCs for high level antigenic and genetic analysis, the result of which forms the basis for WHO recommendations on the composition of influenza vaccine for the Northern and Southern Hemisphere each year."[142]

Formal WHO recommendations were first issued in 1973. Beginning in 1999 there have been two recommendations per year: one for the northern hemisphere and the other for the southern hemisphere.[143]

Due to the widespread use of non-pharmaceutical interventions at the beginning of the COVID-19 pandemic, the B/Yamagata influenza lineage has not been isolated since March 2020, and may have been eradicated. Starting with the 2024 Southern Hemisphere influenza season, the WHO and other regulatory bodies have removed B/Yamagata from influenza vaccine recommendations.[144] [145] [146]

Recommendations

Various public health organizations, including the World Health Organization (WHO), recommend that yearly influenza vaccination be routinely offered, particularly to people at risk of complications of influenza and those individuals who live with or care for high-risk individuals, including:

The flu vaccine is contraindicated for those under six months of age and those with severe, life-threatening allergies to flu vaccine or any ingredient in the vaccine.[148]

World Health Organization

, the World Health Organization (WHO) recommends seasonal influenza vaccination for:[149] [150] [151] [152] [153]

First priority:

Second priority (in no particular order):

Canada

The National Advisory Committee on Immunization (NACI), the group that advises the Public Health Agency of Canada, recommends that everyone over six months of age be encouraged to receive annual influenza vaccination, and that children between the age of six months and 24 months, and their household contacts, should be considered a high priority for the flu vaccine.[154] Particularly:

Live attenuated influenza vaccine (LAIV) was not available in Canada for the 2019–2020 season.

European Union

The European Centre for Disease Prevention and Control (ECDC) recommends vaccinating the elderly as a priority, with a secondary priority people with chronic medical conditions and health care workers.[155]

The influenza vaccination strategy is generally that of protecting vulnerable people, rather than limiting influenza circulation or eliminating human influenza sickness. This is in contrast with the high herd immunity strategies for other infectious diseases such as polio and measles.[156] This is also due in part to the financial and logistics burden associated with the need of an annual injection.[157]

United States

In the United States routine influenza vaccination is recommended for all persons aged six months and over.[158] [159] It takes up to two weeks after vaccination for sufficient antibodies to develop in the body. The CDC recommends vaccination before the end of October, although it considers getting a vaccine in December or even later to be still beneficial.[53] The U.S. military also requires a flu shot annually for its active and reserve servicemembers.[160]

According to the CDC, the live attenuated virus (LAIV4) (which comes in the form of the nasal spray in the US) should be avoided by some groups.[161]

Within its blanket recommendation for general vaccination in the United States, the CDC, which began recommending the influenza vaccine to health care workers in 1981, emphasizes to clinicians the special urgency of vaccination for members of certain vulnerable groups, and their caregivers:

Vaccination is especially important for people at higher risk of serious influenza complications or people who live with or care for people at higher risk for serious complications.[162] In 2009, a new high-dose formulation of the standard influenza vaccine was approved.[163] The Fluzone High Dose is specifically for people 65 and older; the difference is that it has four times the antigen dose of the standard Fluzone.[164] [165] [166] [167]

The US government requires hospitals to report worker vaccination rates. Some US states and hundreds of US hospitals require health care workers to either get vaccinations or wear masks during flu season. These requirements occasionally engender union lawsuits on narrow collective bargaining grounds, but proponents note that courts have generally endorsed forced vaccination laws affecting the general population during disease outbreaks.[168]

Vaccination against influenza is especially considered important for members of high-risk groups who would be likely to have complications from influenza, for example pregnant women[169] and children and teenagers from six months to 18 years of age who are receiving aspirin- or salicylate-containing medications and who might be at risk for experiencing Reye syndrome after influenza virus infection;

The CDC indicated that live attenuated influenza vaccine (LAIV), also called the nasal spray vaccine, was not recommended for the 2016–2017 flu season in the United States.[171]

Furthermore, the CDC recommends that health care personnel who care for severely immunocompromised persons receive injections (TIV or QIV) rather than LAIV.[172]

Australia

The Australian Government recommends seasonal flu vaccination for everyone over the age of six months. Australia uses inactivated vaccines.[173] Until 2021, the egg-based vaccine has been the only one available (and continues to be the only free one), but from March 2021 a new cell-based vaccine is available for those who wish to pay for it, and it is expected that this one will become the standard by 2026.[129] The standard flu vaccine is free for the following people:[174]

Uptake

Vaccination rate in the OECD, 2018 or latest[175]
CountryRegion% aged 65+
Republic of KoreaAsia83
AustraliaOceania75
United KingdomEurope73
United StatesAmericas68
New ZealandOceania65
ChileAmericas65
NetherlandsEurope64
CanadaAmericas61
PortugalEurope61
IsraelAsia58
IrelandEurope58
SpainEurope54
ItalyEurope53
DenmarkEurope52
JapanAsia50
FranceEurope50
SwedenEurope49
FinlandEurope48
IcelandEurope45
LuxembourgEurope38
GermanyEurope35
NorwayEurope34
HungaryEurope27
Czech RepublicEurope20
LithuaniaEurope13
Slovak RepublicEurope13
SloveniaEurope12
LatviaEurope8
TurkeyAsia7
EstoniaEurope5

At risk groups

Uptake of flu vaccination, both seasonally and during pandemics, is often low.[176] Systematic reviews of pandemic flu vaccination uptake have identified several personal factors that may influence uptake, including gender (higher uptake in men), ethnicity (higher in people from ethnic minorities) and having a chronic illness.[177] [178] Beliefs in the safety and effectiveness of the vaccine are also important.

A number of measures have been found to be useful to increase rates of vaccination in those over sixty including: patient reminders using leaflets and letters, postcard reminders, client outreach programs, vaccine home visits, group vaccinations, free vaccinations, physician payment, physician reminders and encouraging physician competition.[179]

Health care workers

Frontline health care workers are often recommended to get seasonal and any pandemic flu vaccination. For example, in the UK all health care workers involved in patient care are recommended to receive the seasonal flu vaccine, and were also recommended to be vaccinated against the H1N1/09 (later renamed A(H1N1)pdm09[180] [181]) swine flu virus during the 2009 pandemic. However, uptake is often low.[182] During the 2009 pandemic, low uptake by healthcare workers was seen in countries including the UK, Italy,[183] Greece,[184] and Hong Kong.[185]

In a 2010 survey of United States health care workers, 63.5% reported that they received the flu vaccine during the 2010–11 season, an increase from 61.9% reported the previous season. US Health professionals with direct patient contact had higher vaccination uptake, such as physicians and dentists (84.2%) and nurse practitioners (82.6%).[186] [187] [188]

The main reason to vaccinate health care workers is to prevent staff from spreading flu to their patients and to reduce staff absence at a time of high service demand, but the reasons health care workers state for their decisions to accept or decline vaccination may more often be to do with perceived personal benefits.

In Victoria (Australia) public hospitals, rates of health care worker vaccination in 2005 ranged from 34% for non-clinical staff to 42% for laboratory staff. One of the reasons for rejecting vaccines was concern over adverse reactions; in one study, 31% of resident physicians at a teaching hospital incorrectly believed Australian vaccines could cause influenza.[189]

Manufacturing

Research continues into the idea of a "universal" influenza vaccine that would not require tailoring to a particular strain, but would be effective against a broad variety of influenza viruses.[190] No vaccine candidates had been announced by November 2007,[191] but, there are several universal vaccines candidates, in pre-clinical development and in clinical trials.[192] [193] [194] [195]

In a 2007 report, the global capacity of approximately 826 million seasonal influenza vaccine doses (inactivated and live) was double the production of 413 million doses. In an aggressive scenario of producing pandemic influenza vaccines by 2013, only 2.8 billion courses could be produced in a six-month time frame. If all high- and upper-middle-income countries sought vaccines for their entire populations in a pandemic, nearly two billion courses would be required. If China pursued this goal as well, more than three billion courses would be required to serve these populations.[196] Vaccine research and development is ongoing to identify novel vaccine approaches that could produce much greater quantities of vaccine at a price that is affordable to the global population.

Egg-based

Most flu vaccines are grown by vaccine manufacturers in fertilized chicken eggs.[197] [191] In the Northern hemisphere, the manufacturing process begins following the announcement (typically in February) of the WHO recommended strains for the winter flu season.[197] [198] Three strains (representing an H1N1, an H3N2, and a B strain) of flu are selected and chicken eggs are inoculated separately. These monovalent harvests are then combined to make the trivalent vaccine.[199]

, both the conventional injection and the nasal spray are manufactured using chicken eggs. The European Union also approved Optaflu, a vaccine produced by Novartis using vats of animal cells. This technique is expected to be more scalable and avoid problems with eggs, such as allergic reactions and incompatibility with strains that affect avians like chickens.[191]

Influenza vaccines are produced in pathogen-free eggs that are eleven or twelve days old.[200] The top of the egg is disinfected by wiping it with alcohol and then the egg is candled to identify a non-veinous area in the allantoic cavity where a small hole is poked to serve as a pressure release.[201] A second hole is made at the top of the egg, where the influenza virus is injected in the allantoic cavity, past the chorioallantoic membrane. The two holes are then sealed with melted paraffin and the inoculated eggs are incubated for 48 hours at 37 degrees Celsius.[200] During incubation time, the virus replicates and newly replicated viruses are released into the allantoic fluid[202]

After the 48-hour incubation period, the top of the egg is cracked and the ten milliliters of allantoic fluid is removed, from which about fifteen micrograms of the flu vaccine can be obtained. At this point, the viruses have been weakened or killed and the viral antigen is purified and placed inside vials, syringes, or nasal sprayers.[202] Up to 3 eggs are needed to produce one dose of a trivalent vaccine, and an estimated 600 million eggs are produced each year for flu vaccine production.[203]

Other methods of manufacture

Methods of vaccine generation that bypass the need for eggs include the construction of influenza virus-like particles (VLP). VLP resemble viruses, but there is no need for inactivation, as they do not include viral coding elements, but merely present antigens in a similar manner to a virion. Some methods of producing VLP include cultures of Spodoptera frugiperda Sf9 insect cells and plant-based vaccine production (e.g., production in Nicotiana benthamiana). There is evidence that some VLPs elicit antibodies that recognize a broader panel of antigenically distinct viral isolates compared to other vaccines in the hemagglutination-inhibition assay (HIA).[204]

A gene-based DNA vaccine, used to prime the immune system after boosting with an inactivated H5N1 vaccine, underwent clinical trials in 2011.[205]

On November 20, 2012, Novartis received FDA approval for the first cell-culture vaccine.[206] [207] [208] [209] In 2013, the recombinant influenza vaccine, Flublok, was approved for use in the United States.[210] [211] [212]

On September 17, 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for Supemtek, a quadrivalent influenza vaccine (recombinant, prepared in cell culture).[213] The applicant for this medicinal product is Sanofi Pasteur. Supemtek was approved for medical use in the European Union in November 2020.[214] [215]

Australia authorised its first and cell-based vaccine in March 2021, based on an "eternal cell line" of a dog kidney. Because of the way it is produced, it produces better-matched vaccine (to the flu strains).[129]

Vaccine manufacturing countries

According to the WHO,, countries where influenza vaccine is produced include:[216]

In addition, Kazakhstan, Serbia and Thailand had facilities in final stages of establishing production.[216]

Cost-effectiveness

The cost-effectiveness of seasonal influenza vaccination has been widely evaluated for different groups and in different settings.[217] In the elderly (over 65), the majority of published studies have found that vaccination is cost saving, with the cost savings associated with influenza vaccination (e.g. prevented health care visits) outweighing the cost of vaccination.[218] In older adults (aged 50–64 years), several published studies have found that influenza vaccination is likely to be cost-effective, however the results of these studies were often found to be dependent on key assumptions used in the economic evaluations.[219] The uncertainty in influenza cost-effectiveness models can partially be explained by the complexities involved in estimating the disease burden,[220] as well as the seasonal variability in the circulating strains and the match of the vaccine.[221] [222] In healthy working adults (aged 18–49 years), a 2012 review found that vaccination was generally not cost-saving, with the suitability for funding being dependent on the willingness to pay to obtain the associated health benefits.[223] In children, the majority of studies have found that influenza vaccination was cost-effective, however many of the studies included (indirect) productivity gains, which may not be given the same weight in all settings.[224] Several studies have attempted to predict the cost-effectiveness of interventions (including prepandemic vaccination) to help protect against a future pandemic, however estimating the cost-effectiveness has been complicated by uncertainty as to the severity of a potential future pandemic and the efficacy of measures against it.[225]

Research

Influenza research includes molecular virology, molecular evolution, pathogenesis, host immune responses, genomics, and epidemiology. These help in developing influenza countermeasures such as vaccines, therapies and diagnostic tools. Improved influenza countermeasures require basic research on how viruses enter cells, replicate, mutate, evolve into new strains and induce an immune response. The Influenza Genome Sequencing Project is creating a library of influenza sequences[226] that will help researchers' understanding of what makes one strain more lethal than another, what genetic determinants most affect immunogenicity, and how the virus evolves over time. Solutions to limitations in current vaccine methods are being researched.

A different approach uses Internet content to estimate the impact of an influenza vaccination campaign. More specifically, researchers have used data from Twitter and Microsoft's Bing search engine, and proposed a statistical framework which, after a series of operations, maps this information to estimates of the influenza-like illness reduction percentage in areas where vaccinations have been performed. The method has been used to quantify the impact of two flu vaccination programmes in England (2013/14 and 2014/15), where school-age children were administered a live attenuated influenza vaccine (LAIV). Notably, the impact estimates were in accordance with estimations from Public Health England based on traditional syndromic surveillance endpoints.[227] [228]

Rapid response to pandemic flu

The rapid development, production, and distribution of pandemic influenza vaccines could potentially save millions of lives during an influenza pandemic. Due to the short time frame between identification of a pandemic strain and need for vaccination, researchers are looking at novel technologies for vaccine production that could provide better "real-time" access and be produced more affordably, thereby increasing access for people living in low- and moderate-income countries, where an influenza pandemic may likely originate, such as live attenuated (egg-based or cell-based) technology and recombinant technologies (proteins and virus-like particles).[229], more than seventy known clinical trials have been completed or are ongoing for pandemic influenza vaccines.[230] In September 2009, the FDA approved four vaccines against the 2009 H1N1 influenza virus (the 2009 pandemic strain), and expected the initial vaccine lots to be available within the following month.[231]

In January 2020, the US Food and Drug Administration (FDA) approved Audenz as a vaccine for the H5N1 flu virus.[232] Audenz is a vaccine indicated for active immunization for the prevention of disease caused by the influenza A virus H5N1 subtype contained in the vaccine. Audenz is approved for use in persons six months of age and older at increased risk of exposure to the influenza A virus H5N1 subtype contained in the vaccine.[233]

Universal flu vaccines

See main article: Universal flu vaccine. A universal influenza vaccine that would not have to be designed and made for each flu season in each hemisphere would stabilize the supply, avoid error in predicting the season's variants, and protect against escape of the circulating strains by mutation. Such a vaccine has been the subject of research for decades.[234]

One approach is to use broadly neutralizing antibodies that, unlike the annual seasonal vaccines used over the first decades of the 21st century that provoke the body to generate an immune response, instead provide a component of the immune response itself. The first neutralizing antibodies were identified in 1993, via experimentation.[235] It was found that the flu neutralizing antibodies bound to the stalk of the Hemagglutinin protein. Antibodies that could bind to the head of those proteins were identified. The highly conserved M2 proton channel was proposed as a potential target for broadly neutralizing antibodies.[234] [236]

The challenges for researchers are to identify single antibodies that could neutralize many subtypes of the virus, so that they could be useful in any season, and that target conserved domains that are resistant to antigenic drift.[234]

Another approach is to take the conserved domains identified from these projects, and to deliver groups of these antigens to provoke an immune response; various approaches with different antigens, presented different ways (as fusion proteins, mounted on virus-like particles, on non-pathogenic viruses, as DNA, and others), are under development.[236] [237] [238]

Efforts have also been undertaken to develop universal vaccines that specifically activate a T-cell response, based on clinical data showing that people with a strong, early T-cell response have better outcomes when infected with influenza and because T-cells respond to conserved epitopes. The challenge for developers is that these epitopes are on internal protein domains that are only mildly immunogenic.[236]

Along with the rest of the vaccine field, people working on universal vaccines have experimented with vaccine adjuvants to improve the ability of their vaccines to create a sufficiently powerful and enduring immune response.[236] [239]

Oral influenza vaccine

As of 2019, an oral flu vaccine was in clinical research.[240] The oral vaccine candidate is based on an adenovirus type5 vector modified to remove genes needed for replication, with an added gene that expresses a small double-stranded RNA hairpin molecule as an adjuvant.[241] In 2020, a PhaseII human trial of the pill form of the vaccine showed that it was well tolerated and provided similar immunity to a licensed injectable vaccine.[242]

COVID-19

An influenza vaccine and a COVID-19 vaccine may be given safely at the same time.[243] [244] Preliminary research indicates that influenza vaccination does not prevent COVID-19, but may reduce the incidence and severity of COVID-19 infection.[245]

Criticism

Tom Jefferson, who has led Cochrane Collaboration reviews of flu vaccines, has called clinical evidence concerning flu vaccines "rubbish" and has therefore declared them to be ineffective; he has called for placebo-controlled randomized clinical trials, which most in the field hold as unethical. His views on the efficacy of flu vaccines are rejected by medical institutions including the CDC and the National Institutes of Health, and by key figures in the field like Anthony Fauci.[246]

Michael Osterholm, who led the Center for Infectious Disease Research and Policy 2012 review on flu vaccines, recommended getting the vaccine but criticized its promotion, saying, "We have overpromoted and overhyped this vaccine... it does not protect as promoted. It's all a sales job: it's all public relations."[247]

Veterinary use

See also: Influenza A virus.

Veterinary influenza vaccination aims to achieve the following four objectives:[248]

  1. Protection from clinical disease
  2. Protection from infection with virulent virus
  3. Protection from virus excretion
  4. Serological differentiation of infected from vaccinated animals (so-called DIVA principle).

Horses

Horses with horse flu can run a fever, have a dry hacking cough, have a runny nose, and become depressed and reluctant to eat or drink for several days but usually recover in two to three weeks. "Vaccination schedules generally require a primary course of two doses, 3–6 weeks apart, followed by boosters at 6–12 month intervals. It is generally recognized that in many cases such schedules may not maintain protective levels of antibody and more frequent administration is advised in high-risk situations."[249]

It is a common requirement at shows in the United Kingdom that horses be vaccinated against equine flu and a vaccination card must be produced; the International Federation for Equestrian Sports (FEI) requires vaccination every six months.[250] [251]

Poultry

It is possible to vaccinate poultry against specific strains of highly pathogenic avian influenza. Vaccination should be combined with other control measures such as infection monitoring, early detection and biosecurity.[252] [253]

Pigs

Swine influenza vaccines are extensively used in pig farming in Europe and North America. Most swine flu vaccines include an H1N1 and an H3N2 strain.

Swine influenza has been recognized as a major problem since the outbreak in 1976. Evolution of the virus has resulted in inconsistent responses to traditional vaccines. Standard commercial swine flu vaccines are effective in controlling the problem when the virus strains match enough to have significant cross-protection. Customised (autogenous) vaccines made from the specific viruses isolated, are made and used in the more difficult cases.[254] The vaccine manufacturer Novartis claims that the H3N2 strain (first identified in 1998) has brought major losses to pig farmers. Abortion storms are a common sign and sows stop eating for a few days and run a high fever. The mortality rate can be as high as fifteen percent.[255]

Dogs

In 2004, influenza A virus subtype H3N8 was discovered to cause canine influenza. Because of the lack of previous exposure to this virus, dogs have no natural immunity to this virus. However, a vaccine was found in 2004.[256]

Further reading

External links

Notes and References

  1. Web site: AusPAR: Influenza Haemagglutinin Recombinant . Therapeutic Goods Administration (TGA) . August 23, 2021 . September 10, 2021 . September 11, 2021 . https://web.archive.org/web/20210911042241/https://www.tga.gov.au/auspar/auspar-influenza-haemagglutinin-recombinant . live .
  2. Web site: AusPAR: Inactivated quadrivalent influenza vaccine (split virion) influenza virus haemagglutinin . Therapeutic Goods Administration (TGA) . December 2, 2020 . September 10, 2021 . September 11, 2021 . https://web.archive.org/web/20210911042252/https://www.tga.gov.au/auspar/auspar-inactivated-quadrivalent-influenza-vaccine-split-virion-influenza-virus-haemagglutinin . live .
  3. Web site: Updates to the Prescribing Medicines in Pregnancy database . Therapeutic Goods Administration (TGA) . December 21, 2022 . January 2, 2023 . April 3, 2022 . https://web.archive.org/web/20220403064059/https://www.tga.gov.au/updates-prescribing-medicines-pregnancy-database . live .
  4. Web site: Prescription medicines: registration of new chemical entities in Australia, 2017 . Therapeutic Goods Administration (TGA) . June 21, 2022 . April 9, 2023 . April 10, 2023 . https://web.archive.org/web/20230410060848/https://www.tga.gov.au/resources/publication/publications/prescription-medicines-registration-new-chemical-entities-australia-2017 . live .
  5. Web site: Prescription medicines: registration of new chemical entities in Australia, 2016 . Therapeutic Goods Administration (TGA) . June 21, 2022 . April 10, 2023 . April 10, 2023 . https://web.archive.org/web/20230410065503/https://www.tga.gov.au/prescription-medicines-registration-new-chemical-entities-australia-2016 . live .
  6. https://www.tga.gov.au/resources/auspar/auspar-flucelvax-quad-0
  7. Web site: Summary Basis of Decision (SBD) for Supemtek . Health Canada . October 23, 2014 . May 29, 2022 . May 30, 2022 . https://web.archive.org/web/20220530043748/https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00528&lang=en . live .
  8. Web site: Regulatory Decision Summary - Flucelvax Quad . Health Canada . October 23, 2014 . June 7, 2022 . June 7, 2022 . https://web.archive.org/web/20220607032927/https://hpr-rps.hres.ca/reg-content/regulatory-decision-summary-detail.php?lang=en&linkID=RDS00579 . live .
  9. Web site: Regulatory Decision Summary - Flucelvax Quad . Health Canada . October 23, 2014 . June 7, 2022 . June 7, 2022 . https://web.archive.org/web/20220607032927/https://hpr-rps.hres.ca/reg-content/regulatory-decision-summary-detail.php?lang=en&linkID=RDS00927 . live .
  10. Web site: Regulatory Decision Summary - Influvac Tetra . Health Canada . October 23, 2014 . June 7, 2022 . June 7, 2022 . https://web.archive.org/web/20220607033342/https://hpr-rps.hres.ca/reg-content/regulatory-decision-summary-detail.php?lang=en&linkID=RDS00571 . live .
  11. Web site: Regulatory Decision Summary for Panenza (Haemagglutinin-Strain A (H1N1)) . Drug and Health Products Portal . October 27, 2023 . April 2, 2024.
  12. Web site: Supemtek EPAR . European Medicines Agency . November 25, 2020 . June 27, 2024.
  13. Web site: Fluad Tetra . European Medicines Agency (EMA) . May 20, 2020 . August 10, 2024.
  14. World Health Organization . World Health Organization . Vaccines against influenza WHO position paper . Weekly Epidemiological Record . 87 . 47 . 461–76 . November 2012 . 23210147 . 10665/241993 . free .
  15. World Health Organization . World Health Organization . Vaccines against influenza: WHO position paper – May 2022 . Weekly Epidemiological Record . 97 . 19 . 185–208 . May 2022 . 10665/354265 . free .
  16. Manzoli L, Ioannidis JP, Flacco ME, De Vito C, Villari P . Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly: a critical review and re-analysis of 15 meta-analyses . Human Vaccines & Immunotherapeutics . 8 . 7 . 851–62 . July 2012 . 22777099 . 3495721 . 10.4161/hv.19917 . John P.A. Ioannidis .
  17. Book: Vaccines for pandemic influenza . Compans RW . 2009 . Springer . 978-3-540-92165-3 . Dordrecht . 49 . September 9, 2017 . https://web.archive.org/web/20200803101300/https://books.google.com/books?id=uOE-3atWZssC&pg=PA49 . August 3, 2020 . live.
  18. Book: Vaccine Analysis: Strategies, Principles, and Control . 2014 . Springer . 978-3-662-45024-6 . 61 . September 9, 2017 . https://web.archive.org/web/20200803141329/https://books.google.com/books?id=vJKeBQAAQBAJ&pg=PA61 . August 3, 2020 . live.
  19. Web site: October 11, 2019 . Who Should and Who Should NOT get a Flu Vaccine . live . https://web.archive.org/web/20191202202838/https://www.cdc.gov/flu/prevent/whoshouldvax.htm . December 2, 2019 . December 2, 2019 . U.S. Centers for Disease Control and Prevention (CDC).
  20. Book: The immunological basis for immunization series: module 23: influenza vaccines . October 2017 . World Health Organization (WHO) . 978-92-4-151305-0 . 10665/259211 . free.
  21. Book: World Health Organization model list of essential medicines: 21st list 2019 . . 2019 . Geneva . 10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO . free . Organization . World Health .
  22. Book: World Health Organization model list of essential medicines: 22nd list (2021) . . 2021 . Geneva . 10665/345533 . WHO/MHP/HPS/EML/2021.02 . free . Organization . World Health .
  23. Web site: Implementation of the Council Recommendation on seasonal influenza vaccination (2009/1019/EU) . . January 2014 . April 10, 2020 . April 10, 2020 . https://web.archive.org/web/20200410223651/https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/Implementation-seasonal-influenza-vaccination-Council-Recommendation-Jan-2014.pdf . live .
  24. Web site: November 25, 2019 . Flu Vaccine and People with Egg Allergies . live . https://web.archive.org/web/20191202200432/https://www.cdc.gov/flu/prevent/egg-allergies.htm . December 2, 2019 . December 2, 2019 . U.S. Centers for Disease Control and Prevention (CDC).
  25. Web site: Intradermal Influenza (Flu) Vaccination . U.S. Centers for Disease Control and Prevention (CDC) . October 31, 2018 . https://web.archive.org/web/20191014052917/https://www.cdc.gov/flu/prevent/qa_intradermal-vaccine.htm . October 14, 2019 . live . October 14, 2019.
  26. Web site: Influenza vaccines – United States, 2019–20 influenza season . U.S. Centers for Disease Control and Prevention (CDC) . August 22, 2019 . https://web.archive.org/web/20191014053637/https://www.cdc.gov/flu/professionals/vaccines.htm . October 14, 2019 . live . October 14, 2019.
  27. Web site: Influenza Virus Vaccine Inactivated . The American Society of Health-System Pharmacists . November 19, 2018 . October 13, 2019 . live . https://web.archive.org/web/20191014051931/https://www.drugs.com/monograph/influenza-virus-vaccine-inactivated.html . October 14, 2019 .
  28. Book: Institute of Medicine . Knobler SL, Mack A, Mahmoud A, Lemon SM . The Threat of Pandemic Influenza: Are We Ready? Workshop Summary . The National Academies Press. 62 . 2005 . 20669448 . 10.17226/11150 . 978-0-309-09504-4 .
  29. Plotkin, S.L. and Plotkin, S.A. "A short history of vaccination". In: Vaccines, Stanley A. Plotkin, Walter A. Orenstein, Paul A. Offit, eds. Elsevier Health Sciences, 2008, pp. 6–7.
  30. Artenstein, A. W. "Influenza" In: Vaccines: A Biography, Andrew W. Artenstein, ed. pp. 191–205.
  31. Hampson AW . Vaccines for pandemic influenza. The history of our current vaccines, their limitations and the requirements to deal with a pandemic threat . Annals of the Academy of Medicine, Singapore . 37 . 6 . 510–17 . June 2008 . 10.47102/annals-acadmedsg.V37N6p510 . 18618064 . 17102174 . free .
  32. Milián E, Kamen AA . Current and emerging cell culture manufacturing technologies for influenza vaccines . Biomed Res Int . 2015 . 504831 . 2015 . 25815321 . 4359798 . 10.1155/2015/504831 . free . doi .
  33. Web site: Cell-Based Flu Vaccines . U.S. Centers for Disease Control and Prevention (CDC) . October 11, 2019 . https://web.archive.org/web/20191202213512/https://www.cdc.gov/flu/prevent/cell-based.htm . December 2, 2019 . live . December 2, 2019.
  34. FDA approves new seasonal influenza vaccine made using novel technology . January 16, 2013 . https://web.archive.org/web/20130518014553/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm335891.htm . May 18, 2013 . U.S. Food and Drug Administration (FDA).
  35. Landry N, Ward BJ, Trépanier S, Montomoli E, Dargis M, Lapini G, Vézina LP . Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza . PLOS ONE . 5 . 12 . e15559 . December 2010 . 21203523 . 3008737 . 10.1371/journal.pone.0015559 . 2010PLoSO...515559L . free . doi .
  36. Osterholm MT . Preparing for the next pandemic . The New England Journal of Medicine . 352 . 18 . 1839–42 . May 2005 . 15872196 . 10.1056/NEJMp058068 . 10.1.1.608.6200 . 45893174 .
  37. Web site: Swine Flu Epidemics. https://web.archive.org/web/19991009112042/http://www.haverford.edu/biology/edwards/disease/viral_essays/warnervirus.htm. October 9, 1999. October 9, 1999.
  38. McCullers JA, Van De Velde LA, Allison KJ, Branum KC, Webby RJ, Flynn PM . Recipients of vaccine against the 1976 "swine flu" have enhanced neutralization responses to the 2009 novel H1N1 influenza virus . Clinical Infectious Diseases . 50 . 11 . 1487–92 . June 2010 . 20415539 . 2946351 . 10.1086/652441 .
  39. Doshi P . September 20, 2018 . Pandemrix vaccine: why was the public not told of early warning signs? . BMJ . 362 . k3948 . 10.1136/bmj.k3948 . 0959-8138 . 52308748 .
  40. Doshi P . Pandemrix vaccine: why was the public not told of early warning signs? . BMJ . 362 . Infographic . September 20, 2018 . 10.1136/bmj.k3948 . 52308748 .
  41. Web site: First Quadrivalent Vaccine Against Seasonal Flu Wins FDA Approval. March 2, 2012. live. https://web.archive.org/web/20120304163117/http://www.medicalnewstoday.com/articles/242385.php. March 4, 2012.
  42. FDA approves first quadrivalent vaccine to prevent seasonal influenza. U.S. Food and Drug Administration (FDA). https://web.archive.org/web/20121221123250/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm294057.htm. December 21, 2012.
  43. Web site: December 14, 2012 Approval Letter – Fluarix Quadrivalent. U.S. Food and Drug Administration (FDA). https://web.archive.org/web/20130102191627/https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm332484.htm. January 2, 2013.
  44. Book: Literature review on quadrivalent influenza vaccines . National Advisory Committee on Immunization (NACI) . July 2014 . Public Health Agency of Canada . Cat.: HP40-117/2014E-PDF Pub.: 140118 . 978-1-100-24682-6 . January 11, 2020 . Ottawa . August 1, 2020 . https://web.archive.org/web/20200801233131/http://publications.gc.ca/collections/collection_2014/aspc-phac/HP40-117-2014-eng.pdf . live .
  45. Web site: What You Should Know for the 2018-2019 Influenza Season . Centers for Disease Control and Prevention (CDC) . January 10, 2019 . February 5, 2020 . August 6, 2020 . https://web.archive.org/web/20200806183316/https://www.cdc.gov/flu/about/season/flu-season-2018-2019.htm . live .
  46. Web site: Fluzone High-Dose Quadrivalent . U.S. Food and Drug Administration (FDA) . November 4, 2019 . February 5, 2020 . STN: BL 103914 . January 12, 2020 . https://web.archive.org/web/20200112032546/https://www.fda.gov/vaccines-blood-biologics/vaccines/fluzone-high-dose-quadrivalent . live .
  47. FDA approves Fluzone High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and older . Sanofi . November 4, 2019 . February 5, 2020 . August 1, 2020 . https://web.archive.org/web/20200801215513/http://www.news.sanofi.us/2019-11-04-FDA-approves-Fluzone-R-High-Dose-Quadrivalent-Influenza-Vaccine-for-adults-65-years-of-age-and-older . live .
  48. Seqirus Receives FDA Approval for Fluad Quadrivalent for Adults 65 Years and Older . Seqirus . February 24, 2020 . August 25, 2020 . August 26, 2020 . https://web.archive.org/web/20200826060136/https://www.seqirus.us/news/seqirus-receives-fda-approval-for-fluad-quadrivalent-for-adults-65-years-and-older . live .
  49. Seqirus Begins Shipping 2020/21 Influenza Vaccines to U.S. Market . Seqirus . July 30, 2020 . August 25, 2020 . August 26, 2020 . https://web.archive.org/web/20200826060135/https://www.seqirus.us/news/seqirus-ships-2020-2021-influenza-vaccines-to-us-market . live .
  50. Koutsakos M, Wheatley AK, Laurie K, Kent SJ, Rockman S . Influenza lineage extinction during the COVID-19 pandemic? . Nature Reviews. Microbiology . 19 . 12 . 741–742 . December 2021 . 34584246 . 8477979 . 10.1038/s41579-021-00642-4 .
  51. Web site: Questions and Answers: Recommended composition of influenza virus vaccines for use in the southern hemisphere 2024 influenza season and development of candidate vaccine viruses for pandemic preparedness . . September 29, 2023 . October 26, 2023 . October 10, 2023 . https://web.archive.org/web/20231010045859/https://cdn.who.int/media/docs/default-source/influenza/who-influenza-recommendations/vcm-southern-hemisphere-recommendation-2024/202309_qanda_recommendation.pdf?sfvrsn=7a6906d1_5 . live .
  52. Web site: WHO advisers recommend switch back to trivalent flu vaccines . Schnirring L . CIDRAP . September 29, 2023 . October 26, 2023 . December 18, 2023 . https://web.archive.org/web/20231218231207/https://www.cidrap.umn.edu/influenza-vaccines/who-advisers-recommend-switch-back-trivalent-flu-vaccines . live .
  53. Web site: Key Facts About Seasonal Flu Vaccine. December 2, 2019. U.S. Centers for Disease Control and Prevention (CDC). https://web.archive.org/web/20191202203516/https://www.cdc.gov/flu/prevent/keyfacts.htm. December 2, 2019. live. December 2, 2019.
  54. Osterholm MT, Kelley NS, Sommer A, Belongia EA . Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis . The Lancet. Infectious Diseases . 12 . 1 . 36–44 . January 2012 . 22032844 . 10.1016/s1473-3099(11)70295-x .
  55. MacIntyre CR, Mahimbo A, Moa AM, Barnes M . Influenza vaccine as a coronary intervention for prevention of myocardial infarction . Heart . 102 . 24 . 1953–1956 . December 2016 . 27686519 . 5256393 . 10.1136/heartjnl-2016-309983 .
  56. Fedson DS . Measuring protection: efficacy versus effectiveness . Developments in Biological Standardization . 95 . 195–201 . 1998 . 9855432 .
  57. Demicheli V, Jefferson T, Ferroni E, Rivetti A, Di Pietrantonj C . February 2018 . Vaccines for preventing influenza in healthy adults . Cochrane Database of Systematic Reviews . 2020 . 2 . CD001269 . 10.1002/14651858.CD001269.pub6 . 6491184 . 29388196 . free . doi.
  58. Jefferson T . Influenza vaccination: policy versus evidence . BMJ . 333 . 7574 . 912–15 . October 2006 . 17068038 . 1626345 . 10.1136/bmj.38995.531701.80 .
  59. Web site: 2007–2008 Influenza (Flu) Season . U.S. Centers for Disease Control and Prevention (CDC) . June 26, 2008 . live . https://web.archive.org/web/20080306061959/http://www.cdc.gov/flu/about/qa/season.htm . March 6, 2008 .
  60. Carrat F, Flahault A . Influenza vaccine: the challenge of antigenic drift . Vaccine . 25 . 39–40 . 6852–6862 . September 2007 . 17719149 . 10.1016/j.vaccine.2007.07.027 .
  61. Sautto GA, Kirchenbaum GA, Ross TM . January 19, 2018 . Towards a universal influenza vaccine: different approaches for one goal . Virology Journal . 15 . 1 . 17 . 10.1186/s12985-017-0918-y . 5785881 . 29370862 . free .
  62. Chow EJ, Doyle JD, Uyeki TM . June 12, 2019 . Influenza virus-related critical illness: prevention, diagnosis, treatment . Critical Care . 23 . 1 . 214 . 10.1186/s13054-019-2491-9 . 6563376 . 31189475 . free .
  63. Krammer F, Smith GJ, Fouchier RA, Peiris M, Kedzierska K, Doherty PC, Palese P, Shaw ML, Treanor J, Webster RG, García-Sastre A . June 28, 2018 . Influenza . Nature Reviews Disease Primers . 4 . 1 . 3 . 10.1038/s41572-018-0002-y . 7097467 . 29955068.
  64. Dabestani NM, Leidner AJ, Seiber EE, Kim H, Graitcer SB, Foppa IM, Bridges CB . September 2019 . A review of the cost-effectiveness of adult influenza vaccination and other preventive services . Preventive Medicine . 126 . 105734 . 10.1016/j.ypmed.2019.05.022 . 6778688 . 31152830.
  65. Ghebrehewet S, MacPherson P, Ho A . December 7, 2016 . Influenza . The BMJ . 355 . i6258 . 10.1136/bmj.i6258 . 5141587 . 27927672.
  66. Principi N, Esposito S . March 4, 2018 . Protection of children against influenza: Emerging problems . Human Vaccines & Immunotherapeutics . 14 . 3 . 750–757 . 10.1080/21645515.2017.1279772 . 5861800 . 28129049.
  67. Thompson MG, Pierse N, Huang QS, Prasad N, Duque J, Newbern EC, Baker MG, Turner N, McArthur C . September 18, 2018 . Influenza vaccine effectiveness in preventing influenza-associated intensive care admissions and attenuating severe disease among adults in New Zealand 2012–2015 . Vaccine . 36 . 39 . 5916–5925 . 10.1016/j.vaccine.2018.07.028 . 30077480 . 51922011 . 0264-410X . April 23, 2022 . May 27, 2022 . https://web.archive.org/web/20220527070911/https://www.sciencedirect.com/science/article/pii/S0264410X18309976 . live .
  68. Tenforde MW, Talbot HK, Trabue CH, Gaglani M, McNeal TS, Monto AS, Martin ET, Zimmerman RK, Silveira FP, Middleton DB, Olson SM . Influenza Vaccine Effectiveness Against Hospitalization in the United States, 2019–2020 . The Journal of Infectious Diseases . December 30, 2020 . 224 . 5 . 813–820 . 10.1093/infdis/jiaa800 . 33378531 . 8408767 . 0022-1899 . April 23, 2022 . April 23, 2022 . https://web.archive.org/web/20220423225806/https://academic.oup.com/jid/article/224/5/813/6055595 . live .
  69. Ferdinands JM, Thompson MG, Blanton L, Spencer S, Grant L, Fry AM . June 23, 2021 . Does influenza vaccination attenuate the severity of breakthrough infections? A narrative review and recommendations for further research . Vaccine . 39 . 28 . 3678–3695 . 10.1016/j.vaccine.2021.05.011 . 34090700 . 235361401 . 0264-410X . April 23, 2022 . April 23, 2022 . https://web.archive.org/web/20220423225806/https://www.sciencedirect.com/science/article/pii/S0264410X21005624 . live .
  70. Ramsay LC, Buchan SA, Stirling RG, Cowling BJ, Feng S, Kwong JC, Warshawsky BF . The impact of repeated vaccination on influenza vaccine effectiveness: a systematic review and meta-analysis . BMC Med . 17 . 1 . 9 . January 2019 . 30626399 . 6327561 . 10.1186/s12916-018-1239-8 . free .
  71. Belongia EA, Skowronski DM, McLean HQ, Chambers C, Sundaram ME, De Serres G . Repeated annual influenza vaccination and vaccine effectiveness: review of evidence . Expert Rev Vaccines . 16 . 7 . 723–36 . July 2017 . 28562111 . 10.1080/14760584.2017.1334554 . free . doi .
  72. Web site: Vaccine Effectiveness: How Well Do the Flu Vaccines Work? . U.S. Centers for Disease Control and Prevention (CDC) . October 12, 2018 . https://web.archive.org/web/20191025023838/https://www.cdc.gov/flu/vaccines-work/vaccineeffect.htm . October 25, 2019 . live . October 24, 2019.
  73. Gemmill I, Young K . June 7, 2018 . Summary of the NACI literature review on the comparative effectiveness of subunit and split virus inactivated influenza vaccines in older adults . Canada Communicable Disease Report . 44 . 6 . 129–133 . 10.14745/ccdr.v44i06a02 . 1481-8531 . 6449119 . 31015805 . June 2, 2020 . May 17, 2020 . https://web.archive.org/web/20200517233323/https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2018-44/issue-6-june-7-2018/article-2-summary-subunit-split-virus-influenza-vaccine.html . live .
  74. Web site: August 26, 2021 . Flu & People 65 Years and Older . April 21, 2022 . Centers for Disease Control and Prevention . April 22, 2022 . https://web.archive.org/web/20220422000747/https://www.cdc.gov/flu/highrisk/65over.htm . live .
  75. MacIntyre CR, Mahimbo A, Moa AM, Barnes M . Influenza vaccine as a coronary intervention for prevention of myocardial infarction . Heart . 102 . 24 . 1953–1956 . December 2016 . 27686519 . 10.1136/heartjnl-2016-309983 . 5256393 .
  76. Web site: Influenza Historic Timeline | Pandemic Influenza (Flu) | CDC. March 11, 2020. January 27, 2022. January 30, 2022. https://web.archive.org/web/20220130090654/https://www.cdc.gov/flu/pandemic-resources/pandemic-timeline-1930-and-beyond.htm. live.
  77. Web site: Influenza (Seasonal) . World Health Organization (WHO) . November 6, 2018 . https://web.archive.org/web/20191025024946/https://www.who.int/en/news-room/fact-sheets/detail/influenza-(seasonal) . October 25, 2019 . live . October 24, 2019.
  78. Web site: Study of Flu-Related Deaths in Children Shows Healthy Children at Risk . U.S. Centers for Disease Control and Prevention (CDC) . February 12, 2018 . https://web.archive.org/web/20191202205242/https://www.cdc.gov/flu/spotlights/2017-2018/flu-death-children.htm . December 2, 2019 . live . December 2, 2019 .
  79. Jefferson T, Rivetti A, Di Pietrantonj C, Demicheli V . Vaccines for preventing influenza in healthy children . Cochrane Database of Systematic Reviews . February 2018 . 2018 . CD004879 . 10.1002/14651858.CD004879.pub5 . 29388195 . 6491174 . free . doi . 2 .
  80. News: U.S. CDC director urges flu vaccinations as pediatric deaths mount. Reuters. January 26, 2018. January 22, 2018. Steenhuysen J. May 6, 2021. https://web.archive.org/web/20210506120529/https://www.reuters.com/article/us-usa-flu-cdc/u-s-cdc-director-urges-flu-vaccinations-as-pediatric-deaths-mount-idUSKBN1FB36O. live.
  81. Web site: Frequently Asked Influenza (Flu) Questions: 2019–2020 Season . U.S. Centers for Disease Control and Prevention (CDC) . November 5, 2019 . https://web.archive.org/web/20191201052345/https://www.cdc.gov/flu/season/faq-flu-season-2019-2020.htm . December 1, 2019 . live . November 30, 2019.
  82. Web site: Fluzone High-Dose Quadrivalent . U.S. Food and Drug Administration (FDA) . November 14, 2019 . https://web.archive.org/web/20191201060617/https://www.fda.gov/vaccines-blood-biologics/vaccines/fluzone-high-dose-quadrivalent . December 1, 2019 . live . November 30, 2019.
  83. Web site: Afluria Quadrivalent . U.S. Food and Drug Administration (FDA) . November 8, 2019 . https://web.archive.org/web/20191201060305/https://www.fda.gov/vaccines-blood-biologics/vaccines/afluria-quadrivalent . December 1, 2019 . live . November 30, 2019.
  84. Web site: Supplemental Statement – Afluria Tetra – An Advisory Committee Statement (ACS) . National Advisory Committee on Immunization (NACI) . Public Health Agency of Canada . November 2018 . Cat.: HP37-25E-PDF Pub.: 180566 . January 11, 2020 . Ottawa . January 12, 2020 . https://web.archive.org/web/20200112032215/https://www.canada.ca/en/public-health/services/publications/healthy-living/supplemental-statement-afluria-tetra.html . live .
  85. Literature review on influenza vaccination in healthy 5–18-year-olds . Public Health Agency of Canada . July 2014 . Cat.: HP40-116/2014E-PDF Pub.: 140116 . 978-1-100-24681-9 . Ottawa . January 12, 2020 . August 1, 2020 . https://web.archive.org/web/20200801221759/http://publications.gc.ca/collections/collection_2014/aspc-phac/HP40-116-2014-eng.pdf . live .
  86. Literature Review on Pediatric Fluad Influenza Vaccine Use in Children 6–72 Months of Age . 2015 . Public Health Agency of Canada . January 11, 2020 . Ottawa . May 17, 2020 . https://web.archive.org/web/20200517230456/https://www.canada.ca/content/dam/phac-aspc/migration/phac-aspc/naci-ccni/assets/pdf/pediatric-pediatrique-fluad-eng.pdf . live .
  87. Peleg N, Zevit N, Shamir R, Chodick G, Levy I . Seasonal influenza vaccination rates and reasons for non-vaccination in children with gastrointestinal disorders . Vaccine . 33 . 1 . 182–186 . January 2015 . 25444802 . 10.1016/j.vaccine.2014.10.086 .
  88. Osterholm MT, Kelley NS, Sommer A, Belongia EA . January 2012 . Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis . The Lancet. Infectious Diseases . 12 . 1 . 36–44 . 10.1016/S1473-3099(11)70295-X . 22032844.
  89. Burls A, Jordan R, Barton P, Olowokure B, Wake B, Albon E, Hawker J . Vaccinating healthcare workers against influenza to protect the vulnerable – is it a good use of healthcare resources? A systematic review of the evidence and an economic evaluation . Vaccine . 24 . 19 . 4212–21 . May 2006 . 16546308 . 10.1016/j.vaccine.2005.12.043 .
  90. Ahmed F, Lindley MC, Allred N, Weinbaum CM, Grohskopf L . Effect of influenza vaccination of healthcare personnel on morbidity and mortality among patients: systematic review and grading of evidence . Clinical Infectious Diseases . 58 . 1 . 50–57 . January 2014 . 24046301 . 10.1093/cid/cit580 . free . doi .
  91. Griffin MR . Influenza vaccination of healthcare workers: making the grade for action . Clinical Infectious Diseases . 58 . 1 . 58–60 . January 2014 . 24046312 . 10.1093/cid/cit590 . free . doi .
  92. Simonsen L, Viboud C, Taylor RJ, Miller MA, Jackson L . Influenza vaccination and mortality benefits: new insights, new opportunities . Vaccine . 27 . 45 . 6300–04 . October 2009 . 19840664 . 10.1016/j.vaccine.2009.07.008 .
  93. Demicheli V, Jefferson T, Di Pietrantonj C, Ferroni E, Thorning S, Thomas RE, Rivetti A . February 2018 . Vaccines for preventing influenza in the elderly . Cochrane Database of Systematic Reviews . 2 . 11 . CD004876 . 10.1002/14651858.CD004876.pub4 . 6491101 . 29388197 . free . doi.
  94. Darvishian M, Bijlsma MJ, Hak E, van den Heuvel ER . Effectiveness of seasonal influenza vaccine in community-dwelling elderly people: a meta-analysis of test-negative design case-control studies . The Lancet. Infectious Diseases . 14 . 12 . 1228–39 . December 2014 . 25455990 . 10.1016/S1473-3099(14)70960-0 .
  95. Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E . Effectiveness of influenza vaccine in the community-dwelling elderly . The New England Journal of Medicine . 357 . 14 . 1373–81 . October 2007 . 17914038 . 10.1056/NEJMoa070844 . 14850833 . free .
  96. Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA . Mortality benefits of influenza vaccination in elderly people: an ongoing controversy . The Lancet. Infectious Diseases . 7 . 10 . 658–66 . October 2007 . 17897608 . 10.1016/S1473-3099(07)70236-0 .
  97. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K . Mortality associated with influenza and respiratory syncytial virus in the United States . JAMA . 289 . 2 . 179–86 . January 2003 . 12517228 . 10.1001/jama.289.2.179 . 5018362 . free .
  98. Web site: High Dose Flu Vaccine for the Elderly « Science-Based Medicine . October 19, 2010 . Sciencebasedmedicine.org . October 17, 2013 . live . https://web.archive.org/web/20130508081643/http://www.sciencebasedmedicine.org/index.php/high-dose-flu-vaccine-for-the-elderly/ . May 8, 2013 .
  99. Web site: Fluzone High-Dose Seasonal Influenza Vaccine . U.S. Centers for Disease Control and Prevention (CDC) . September 6, 2019 . https://web.archive.org/web/20191202211420/https://www.cdc.gov/flu/prevent/qa_fluzone.htm . December 2, 2019 . live . December 2, 2019.
  100. DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, Pollak R, Christoff J, Earl J, Landolfi V, Martin E, Gurunathan S, Nathan R, Greenberg DP, Tornieporth NG, Decker MD, Talbot HK . Efficacy of high-dose versus standard-dose influenza vaccine in older adults . The New England Journal of Medicine . 371 . 7 . 635–45 . August 2014 . 25119609 . 10.1056/NEJMoa1315727 . 205096393 . free .
  101. High Dose Influenza Vaccine for Adults: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines . Rapid Response Report . January 8, 2019 . Wells C, Grobelna A . 1922-8147 . Canadian Agency for Drugs and Technologies in Health (CADTH) . Ottawa . 31141324 . August 15, 2022 . August 1, 2020 . https://web.archive.org/web/20200801200034/https://cadth.ca/sites/default/files/pdf/htis/2018/RC1059%20High%20Dose%20Flu%20Vaccine%20Final.pdf . live .
  102. Mascagni P, Vicenzi E, Kajaste-Rudnitski A, Pellicciotta G, Monti A, Cervi C, Vitalucci R, Toffoletto F . Assessment of efficacy and safety of pandemic A/H1N1/2009 influenza vaccine in a group of health care workers . La Medicina del Lavoro . 103 . 3 . 220–29 . 2012 . 22838300 .
  103. FDA approves first seasonal influenza vaccine containing an adjuvant . November 24, 2015 . U.S. Food and Drug Administration (FDA) . August 20, 2017 . https://web.archive.org/web/20170722061508/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm474295.htm . July 22, 2017 .
  104. Web site: Fluad . U.S. Food and Drug Administration (FDA) . November 8, 2019 . https://web.archive.org/web/20191202210615/https://www.fda.gov/vaccines-blood-biologics/vaccines/fluad . December 2, 2019 . live . December 2, 2019 . STN 125510.
  105. Influenza vaccine with squalene adjuvant: new preparation. No better than available products . Prescrire International . 13 . 74 . 206–08 . December 2004 . 15599987 .
  106. Camilloni B, Basileo M, Valente S, Nunzi E, Iorio AM . Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review . Human Vaccines & Immunotherapeutics . 11 . 3 . 553–63 . 2015 . 25714138 . 4514405 . 10.1080/21645515.2015.1011562.
  107. Van Damme P, Arnou R, Kafeja F, Fiquet A, Richard P, Thomas S, Meghlaoui G, Samson SI, Ledesma E . Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study . BMC Infectious Diseases . 10 . 134 . May 2010 . 20504306 . 2895601 . 10.1186/1471-2334-10-134 . free .
  108. Web site: Flu Vaccine With Adjuvant . U.S. Centers for Disease Control and Prevention (CDC) . September 4, 2019 . https://web.archive.org/web/20191202210120/https://www.cdc.gov/flu/prevent/adjuvant.htm . December 2, 2019 . live . December 2, 2019.
  109. Haverkate M, D'Ancona F, Giambi C, Johansen K, Lopalco PL, Cozza V, Appelgren E . VENICE project gatekeepers contact points collective . Mandatory and recommended vaccination in the EU, Iceland and Norway: results of the VENICE 2010 survey on the ways of implementing national vaccination programmes . Euro Surveillance . 17 . 22 . May 2012 . 22687916 . 10.2807/ese.17.22.20183-en . free . doi .
  110. Field RI . Mandatory vaccination of health care workers: whose rights should come first? . P & T . 34 . 11 . 615–18 . November 2009 . 20140133 . 2810172 .
  111. Kassianos G . Willingness of European healthcare workers to undergo vaccination against seasonal influenza: current situation and suggestions for improvement . Drugs in Context . 4 . 212268 . 2015 . 25657810 . 4316812 . 10.7573/dic.212268 .
  112. Thomas RE, Jefferson T, Lasserson TJ . Influenza vaccination for healthcare workers who care for people aged 60 or older living in long-term care institutions . The Cochrane Database of Systematic Reviews . 6 . CD005187 . June 2016 . 2016 . 27251461 . 10.1002/14651858.CD005187.pub5 . 8504984 . free . doi .
  113. Web site: Fluad Quad Australian prescription medicine decision summary . Therapeutic Goods Administration (TGA) . December 13, 2019 . August 24, 2020 . March 8, 2020 . https://web.archive.org/web/20200308183218/https://www.tga.gov.au/apm-summary/fluad-quad . live .
  114. Web site: Fluad Quadrivalent . U.S. Food and Drug Administration (FDA) . July 2, 2020 . August 25, 2020 . STN: 125510 . August 11, 2020 . https://web.archive.org/web/20200811160311/https://www.fda.gov/vaccines-blood-biologics/fluad-quadrivalent . live .
  115. Web site: Fluad Tetra EPAR . European Medicines Agency (EMA) . March 24, 2020 . May 29, 2020 . August 1, 2020 . https://web.archive.org/web/20200801205143/https://www.ema.europa.eu/en/medicines/human/EPAR/fluad-tetra . live .
  116. Web site: Fluad Tetra Product information . Union Register of medicinal products . March 3, 2023 . March 5, 2023 . https://web.archive.org/web/20230305070644/https://ec.europa.eu/health/documents/community-register/html/h1433.htm . live .
  117. Fell DB, Sprague AE, Liu N, Yasseen AS, Wen SW, Smith G, Walker MC . H1N1 influenza vaccination during pregnancy and fetal and neonatal outcomes . American Journal of Public Health . 102 . 6 . e33–40 . June 2012 . 22515877 . 3483960 . 10.2105/AJPH.2011.300606 . Submitted manuscript .
  118. Madhi SA, Cutland CL, Kuwanda L, Weinberg A, Hugo A, Jones S, Adrian PV, van Niekerk N, Treurnicht F, Ortiz JR, Venter M, Violari A, Neuzil KM, Simões EA, Klugman KP, Nunes MC . Influenza vaccination of pregnant women and protection of their infants . The New England Journal of Medicine . 371 . 10 . 918–31 . September 2014 . 25184864 . 10.1056/NEJMoa1401480 . 2263/42412 . free .
  119. Web site: Flu shot . CDC . September 24, 2020 . 2020 . December 2, 2019 . https://web.archive.org/web/20191202232426/https://www.cdc.gov/flu/prevent/flushot.htm . live .
  120. Web site: Misconceptions about flu vaccines . CDC . September 24, 2020 . 2020 . August 10, 2020 . https://web.archive.org/web/20200810162228/https://www.cdc.gov/flu/prevent/misconceptions.htm . live .
  121. News: McNeil Jr . Donald G . October 1, 2018 . Over 80,000 Americans Died of Flu Last Winter, Highest Toll in Years . live . https://web.archive.org/web/20181001182236/https://www.nytimes.com/2018/10/01/health/flu-deaths-vaccine.html . October 1, 2018 . June 24, 2024 . The New York Times.
  122. Web site: 5 myths about the flu vaccine . live . https://web.archive.org/web/20240214132129/https://www.who.int/news-room/spotlight/influenza-are-we-ready/5-myths-about-the-flu-vaccine . February 14, 2024 . June 24, 2024 . World Health Organization.
  123. Haber P, Sejvar J, Mikaeloff Y, DeStefano F . Vaccines and Guillain-Barré syndrome . Drug Safety . 32 . 4 . 309–23 . 2009 . 19388722 . 10.2165/00002018-200932040-00005 . 33670594 .
  124. Reorganized text . JAMA Otolaryngology–Head & Neck Surgery . 141 . 5 . 428 . May 2015 . 25996397 . 10.1001/jamaoto.2015.0540 . 26612829 .
  125. Stowe J, Andrews N, Wise L, Miller E . Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenza-like illness using the United Kingdom General Practice Research Database . American Journal of Epidemiology . 169 . 3 . 382–88 . February 2009 . 19033158 . 10.1093/aje/kwn310 . free . doi .
  126. Sivadon-Tardy V, Orlikowski D, Porcher R, Sharshar T, Durand MC, Enouf V, Rozenberg F, Caudie C, Annane D, van der Werf S, Lebon P, Raphaël JC, Gaillard JL, Gault E . Guillain-Barré syndrome and influenza virus infection . Clinical Infectious Diseases . 48 . 1 . 48–56 . January 2009 . 19025491 . 10.1086/594124 . free . doi .
  127. Vellozzi C, Burwen DR, Dobardzic A, Ball R, Walton K, Haber P . Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring . Vaccine . 27 . 15 . 2114–20 . March 2009 . 19356614 . 10.1016/j.vaccine.2009.01.125 . May 21, 2020 . August 1, 2020 . https://web.archive.org/web/20200801190854/https://zenodo.org/record/1259425 . live .
  128. News: Last Year's H1N1 Flu Vaccine Was Safe, Study Finds. February 2, 2011. Reinberg S . U.S. News & World Report. live. https://web.archive.org/web/20130425164738/http://health.usnews.com/health-news/managing-your-healthcare/research/articles/2011/02/02/last-years-h1n1-flu-vaccine-was-safe-study-finds. April 25, 2013 .
  129. News: March 27, 2021 . Australia's first cell-based influenza vaccines to roll out this flu season . ABC News . live . April 28, 2021 . https://web.archive.org/web/20210427180254/https://www.abc.net.au/news/health/2021-03-27/flu-new-vaccine-cell-based-australian-first/100023908 . April 27, 2021 . Roberts L.
  130. National Advisory Committee on Immunization (NACI) . Statement on Seasonal Influenza Vaccine for 2012–2013. Canada Communicable Disease Report. August 2012. 38. https://web.archive.org/web/20130117234635/http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/12vol38/acs-dcc-2/assets/pdf/acs-dcc-2-eng.pdf. January 17, 2013. July 18, 2013 . Ottawa .
  131. Turner PJ, Southern J, Andrews NJ, Miller E, Erlewyn-Lajeunesse M . Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study . BMJ . 351 . h6291 . December 2015 . 26645895 . 4673102 . 10.1136/bmj.h6291 .
  132. Greenhawt M . Live attenuated influenza vaccine for children with egg allergy . BMJ . 351 . h6656 . December 2015 . 26657778 . 10.1136/bmj.h6656 . 37037904 .
  133. Book: Technical Report: Narcolepsy in association with pandemic influenza vaccination. 2012. European Centre for Disease Prevention and Control (ECDC). Stockholm, Sweden. 978-92-9193-388-4. https://web.archive.org/web/20131231001407/http://www.ecdc.europa.eu/en/publications/Publications/Vaesco%20report%20FINAL%20with%20cover.pdf. December 31, 2013. December 30, 2013.
  134. 10.1038/nature.2013.14413 . Narcolepsy confirmed as autoimmune disease . Nature . 2013 . Yong E . 74850662 .
  135. Web site: Thimerosal in Flu Vaccine . . October 16, 2015 . https://web.archive.org/web/20191202222555/https://www.cdc.gov/flu/prevent/thimerosal.htm . December 2, 2019 . live . December 2, 2019.
  136. Web site: Thimerosal in Vaccines Thimerosal – Concerns – Vaccine Safety . . October 27, 2015 . https://web.archive.org/web/20191102181824/https://www.cdc.gov/vaccinesafety/concerns/thimerosal/index.html . November 2, 2019 . live . December 2, 2019.
  137. Offit PA . Thimerosal and vaccines – a cautionary tale . The New England Journal of Medicine . 357 . 13 . 1278–79 . September 2007 . 17898096 . 10.1056/NEJMp078187 . 36318722 . free .
  138. Web site: Thiomersal and vaccines . Global Advisory Committee on Vaccine Safety . World Health Organization (WHO) . July 14, 2006 . November 20, 2007 . https://web.archive.org/web/20091106092438/http://www.who.int/vaccine_safety/topics/thiomersal/en/index.html . November 6, 2009 .
  139. Book: Plotkin SA, Orenstein WA . Vaccines. 1988. W.B. Saunders Company. Philadelphia. 978-0-7216-1946-0. registration . 424. September 7, 2020.
  140. Web site: Global Influenza Surveillance and Response System (GISRS) . https://web.archive.org/web/20111003070329/http://www.who.int/influenza/gisrs_laboratory/en/ . October 3, 2011 . World Health Organization . October 22, 2019.
  141. Web site: Spotlight: Influenza . World Health Organization . October 22, 2019 . October 18, 2019 . https://web.archive.org/web/20191018013229/https://www.who.int/influenza/spotlight . live .
  142. Web site: Global influenza surveillance . WHO . https://web.archive.org/web/20030430160359/http://www.who.int/csr/disease/influenza/influenzanetwork/en/index.html . April 30, 2003 .
  143. Book: WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases – Influenza . World Health Organization (WHO) . 2000 . WHO/CDS/CSR/ISR/2000/1 . 10665/66485 . free . Organization . World Health .
  144. Web site: Schnirring . Lisa . WHO advisers recommend switch back to trivalent flu vaccines . . September 29, 2023 . January 23, 2024 . https://web.archive.org/web/20231218231207/https://www.cidrap.umn.edu/influenza-vaccines/who-advisers-recommend-switch-back-trivalent-flu-vaccines . December 18, 2023 . live.
  145. Web site: Use of Trivalent Influenza Vaccines for the 2024-2025 U.S. flu season . U.S. Food and Drug Administration (FDA) . March 5, 2024 . March 7, 2024 . March 7, 2024 . https://web.archive.org/web/20240307043000/https://www.fda.gov/vaccines-blood-biologics/lot-release/use-trivalent-influenza-vaccines-2024-2025-us-influenza-season . live .
  146. Web site: EU recommendations for 2024/2025 seasonal flu vaccine composition . European Medicines Agency (EMA) . March 26, 2024 . March 28, 2024 . March 28, 2024 . https://web.archive.org/web/20240328064245/https://www.ema.europa.eu/en/news/eu-recommendations-2024-2025-seasonal-flu-vaccine-composition . live .
  147. To KW, Lai A, Lee KC, Koh D, Lee SS . Increasing the coverage of influenza vaccination in healthcare workers: review of challenges and solutions . The Journal of Hospital Infection . 94 . 2 . 133–42 . October 2016 . 27546456 . 10.1016/j.jhin.2016.07.003 .
  148. Web site: Seasonal Flu Shot . U.S. Centers for Disease Control and Prevention (CDC) . December 9, 2019 . January 12, 2020 . December 2, 2019 . https://web.archive.org/web/20191202232426/https://www.cdc.gov/flu/prevent/flushot.htm . live .
  149. Web site: Vaccine use . World Health Organization (WHO) . January 15, 2017 . https://web.archive.org/web/20121215120730/http://www.who.int/influenza/vaccines/use/en/ . December 15, 2012 .
  150. Web site: Influenza (Seasonal) Fact sheet . World Health Organization (WHO) . November 2016 . January 15, 2017 . live . https://web.archive.org/web/20141130051058/http://www.who.int/mediacentre/factsheets/fs211/en/ . November 30, 2014 .
  151. Web site: Influenza (Seasonal) . WHO . November 6, 2018 . https://web.archive.org/web/20191014062745/https://www.who.int/en/news-room/fact-sheets/detail/influenza-(seasonal) . October 14, 2019 . live . October 14, 2019.
  152. Web site: Methods for assessing influenza vaccination coverage in target groups (2016) . WHO/Europe . March 19, 2018 . October 14, 2019 . October 14, 2019 . https://web.archive.org/web/20191014063302/http://www.euro.who.int/en/health-topics/communicable-diseases/influenza/publications/2016/methods-for-assessing-influenza-vaccination-coverage-in-target-groups-2016 . live .
  153. Web site: Recommendations on influenza vaccination during the 2019–2020 winter season . WHO/Europe . September 24, 2019 . October 14, 2019 . October 14, 2019 . https://web.archive.org/web/20191014063259/http://www.euro.who.int/en/health-topics/communicable-diseases/influenza/publications/2019/recommendations-on-influenza-vaccination-during-the-20192020-winter-season-2019 . live .
  154. Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2019–2020 . May 2019 . Public Health Agency of Canada . Cat.: HP37-25E-PDF; Pub.: 180883 . June 2, 2020 . July 16, 2020 . https://web.archive.org/web/20200716080446/https://www.canada.ca/content/dam/phac-aspc/documents/services/publications/healthy-living/canadian-immunization-guide-statement-seasonal-influenza-vaccine-2019-2020/NACI_Stmt_on_Seasonal_Influenza_Vaccine_2019-2020_v12.3_EN.pdf . live .
  155. Web site: Risk groups for severe influenza . European Centre for Disease Prevention and Control (ECDC) . October 20, 2017 . https://web.archive.org/web/20191022071926/https://www.ecdc.europa.eu/en/seasonal-influenza/prevention-and-control/vaccines/risk-groups . October 22, 2019 . live . October 22, 2019.
  156. News: ECDC Reviews – New WHO recommendations on seasonal influenza .... December 25, 2016. European Centre for Disease Prevention and Control (ECDC). live. https://web.archive.org/web/20170510115326/http://ecdc.europa.eu/en/activities/sciadvice/_layouts/forms/Review_DispForm.aspx?List=a3216f4c-f040-4f51-9f77-a96046dbfd72&ID=698. May 10, 2017.
  157. Web site: ECDC Guidance: Priority risk groups for influenza vaccination . 7–8 . European Centre for Disease Prevention and Control (ECDC) . December 25, 2016 . https://web.archive.org/web/20161225214347/http://ecdc.europa.eu/en/publications/Publications/0808_GUI_Priority_Risk_Groups_for_Influenza_Vaccination.pdf . December 25, 2016 .
  158. Grohskopf LA, Alyanak E, Ferdinands JM, Broder KR, Blanton LH, Talbot HK, Fry AM . Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021-22 Influenza Season . MMWR Recomm Rep . 70 . 5 . 1–28 . August 2021 . 34448800 . 10.15585/mmwr.rr7005a1 . 8407757 . free . doi . August 29, 2021 . August 27, 2021 . https://web.archive.org/web/20210827010217/https://www.cdc.gov/mmwr/volumes/70/rr/pdfs/rr7005a1-H.pdf . live .
  159. Web site: Children & Influenza (Flu). U.S. Centers for Disease Control and Prevention (CDC). October 23, 2019. live. https://web.archive.org/web/20191111042856/https://www.cdc.gov/flu/highrisk/children.htm. November 11, 2019.
  160. News: Rahman . Khaleda . October 21, 2021 . Full List of Vaccines Mandated by the U.S. Military . live . https://web.archive.org/web/20231219004334/https://www.newsweek.com/list-vaccines-mandated-us-military-covid-1641228 . December 19, 2023 . Newsweek.
  161. Web site: Live Attenuated Influenza Vaccine [LAIV] (The Nasal Spray Flu Vaccine) ]. U.S. Centers for Disease Control and Prevention (CDC) . September 16, 2019 . https://web.archive.org/web/20191014221155/https://www.cdc.gov/flu/prevent/nasalspray.htm . October 14, 2019 . live . October 14, 2019.
  162. Web site: Influenza Vaccination: A Summary for Clinicians – Health Professionals – Seasonal Influenza (Flu). U.S. Centers for Disease Control and Prevention (CDC). live. https://web.archive.org/web/20080224040716/http://www.cdc.gov/flu/professionals/vaccination/vax-summary.htm. February 24, 2008. September 6, 2018.
  163. Web site: Fluzone, Fluzone High-Dose and Fluzone Intradermal . U.S. Food and Drug Administration (FDA) . July 11, 2017 . July 22, 2017 . https://wayback.archive-it.org/7993/20170722071642/https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm112854.htm . live . June 1, 2020.
  164. Couch RB, Winokur P, Brady R, Belshe R, Chen WH, Cate TR, Sigurdardottir B, Hoeper A, Graham IL, Edelman R, He F, Nino D, Capellan J, Ruben FL . Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects . Vaccine . 25 . 44 . 7656–63 . November 2007 . 17913310 . 2243220 . 10.1016/j.vaccine.2007.08.042 .
  165. Lee JK, Lam GK, Shin T, Kim J, Krishnan A, Greenberg DP, Chit A . Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis . Expert Rev Vaccines . 17 . 5 . 435–443 . May 2018 . 29715054 . 10.1080/14760584.2018.1471989 . 21688517 .
  166. Robertson CA, DiazGranados CA, Decker MD, Chit A, Mercer M, Greenberg DP . Fluzone High-Dose Influenza Vaccine . Expert Rev Vaccines . 15 . 12 . 1495–1505 . December 2016 . 27813430 . 10.1080/14760584.2016.1254044 . free . doi .
  167. Literature review update on the efficacy and effectiveness of high-dose (Fluzone High-Dose) and MF59-adjuvanted (Fluad) trivalent inactivated influenza vaccines in adults 65 years of age and older . HP40-210/2018E-PDF . Ottawa . Public Health Agency of Canada . May 2018 . June 1, 2020 . July 21, 2020 . https://web.archive.org/web/20200721210629/http://publications.gc.ca/collections/collection_2018/aspc-phac/HP40-210-2018-eng.pdf . live .
  168. Web site: Tanner L . Hospitals crack down on workers who refuse flu shots . NBC News . January 13, 2013 . July 24, 2014 . live . https://web.archive.org/web/20131203052836/https://www.nbcnews.com/health/hospitals-crack-down-workers-who-refuse-flu-shots-1B7956764 . December 3, 2013 .
  169. Seasonal influenza and 2009 H1N1 influenza vaccination coverage among pregnant women – 10 states, 2009–10 influenza season . Morbidity and Mortality Weekly Report (MMWR). 59 . 47 . 1541–45 . December 2010 . 21124293 . https://web.archive.org/web/20170625002726/https://www.cdc.gov/mmwr/PDF/wk/mm5947.pdf . live . June 25, 2017 . Centers for Disease Control Prevention (CDC).
  170. News: The New York Times. Altman LK . February 28, 2008. Panel Advises Flu Shots for Children Up to Age 18. live. https://web.archive.org/web/20150122091530/http://www.nytimes.com/2008/02/28/health/28flu.html. January 22, 2015 .
  171. ACIP votes down use of LAIV for 2016–2017 flu season. June 22, 2016. November 26, 2016. U.S. Centers for Disease Control and Prevention (CDC). live. https://web.archive.org/web/20161125075847/http://www.cdc.gov/media/releases/2016/s0622-laiv-flu.html. November 25, 2016.
  172. Web site: Immunization Schedules. U.S. Centers for Disease Control and Prevention (CDC). November 4, 2014. live. https://web.archive.org/web/20141105025622/http://www.cdc.gov/vaccines/schedules/hcp/imz/adult-conditions.html. November 5, 2014.
  173. Web site: Flu vaccine FAQs. Healthdirect, Department of Health, Government of Australia. May 29, 2019. April 1, 2019. May 29, 2019. https://web.archive.org/web/20190529043146/https://www.healthdirect.gov.au/flu-vaccine-faqs. live.
  174. Web site: Influenza fact sheet. Healthdirect, Department of Health, Government of Australia. May 29, 2019. April 1, 2019. May 29, 2019. https://web.archive.org/web/20190529043157/https://www.health.nsw.gov.au/Infectious/factsheets/Pages/influenza_factsheet.aspx. live.
  175. Web site: Health care use – Influenza vaccination rates – OECD Data . theOECD . April 24, 2020 . August 8, 2020 . https://web.archive.org/web/20200808035928/https://data.oecd.org/healthcare/influenza-vaccination-rates.htm#indicator-chart . live .
  176. Han YK, Michie S, Potts HW, Rubin GJ . Predictors of influenza vaccine uptake during the 2009/10 influenza A H1N1v ('swine flu') pandemic: Results from five national surveys in the United Kingdom . Preventive Medicine . 84 . 57–61 . March 2016 . 26757401 . 4766366 . 10.1016/j.ypmed.2015.12.018 .
  177. Bish A, Yardley L, Nicoll A, Michie S . Factors associated with uptake of vaccination against pandemic influenza: a systematic review . Vaccine . 29 . 38 . 6472–84 . September 2011 . 21756960 . 10.1016/j.vaccine.2011.06.107 .
  178. Brien S, Kwong JC, Buckeridge DL . The determinants of 2009 pandemic A/H1N1 influenza vaccination: a systematic review . Vaccine . 30 . 7 . 1255–64 . February 2012 . 22214889 . 10.1016/j.vaccine.2011.12.089 .
  179. Thomas RE, Lorenzetti DL . Interventions to increase influenza vaccination rates of those 60 years and older in the community . The Cochrane Database of Systematic Reviews . 5 . CD005188 . May 2018 . 29845606 . 6494593 . 10.1002/14651858.CD005188.pub4 . free . doi . 5 .
  180. (H1N1)pdm09 is newer nomenclature for the 2009 pandemic H1N1 virus, not a different strain.
  181. Update on influenza A (H1N1) 2009 monovalent vaccines . Morbidity and Mortality Weekly Report (MMWR). 58 . 39 . 1100–01 . October 2009 . 19816398 . https://web.archive.org/web/20110629132344/http://www.cdc.gov/mmwr/pdf/wk/mm5839.pdf . live . June 29, 2011 . Centers for Disease Control Prevention (CDC).
  182. Rubin GJ, Potts HW, Michie S . Likely uptake of swine and seasonal flu vaccines among healthcare workers. A cross-sectional analysis of UK telephone survey data . Vaccine . 29 . 13 . 2421–28 . March 2011 . 21277402 . 10.1016/j.vaccine.2011.01.035 .
  183. La Torre G, Di Thiene D, Cadeddu C, Ricciardi W, Boccia A . Behaviours regarding preventive measures against pandemic H1N1 influenza among Italian healthcare workers, October 2009 . Euro Surveillance . 14 . 49 . December 2009 . 20003908 .
  184. Amodio E, Anastasi G, Marsala MG, Torregrossa MV, Romano N, Firenze A . Vaccination against the 2009 pandemic influenza A (H1N1) among healthcare workers in the major teaching hospital of Sicily (Italy) . Vaccine . 29 . 7 . 1408–12 . February 2011 . 21199700 . 10.1016/j.vaccine.2010.12.041 .
  185. Chor JS, Ngai KL, Goggins WB, Wong MC, Wong SY, Lee N, Leung TF, Rainer TH, Griffiths S, Chan PK . Willingness of Hong Kong healthcare workers to accept pre-pandemic influenza vaccination at different WHO alert levels: two questionnaire surveys . BMJ . 339 . b3391 . August 2009 . 19706937 . 2731837 . 10.1136/bmj.b3391 .
  186. Web site: CDC updates flu vaccination recommendations . Schnirring L . Center for Infectious Disease Research and Policy (CIDRAP) . August 18, 2011. https://web.archive.org/web/20191025025948/http://www.cidrap.umn.edu/news-perspective/2011/08/cdc-updates-flu-vaccination-recommendations . October 25, 2019 . live . October 24, 2019 .
  187. Influenza vaccination coverage among health-care personnel – United States, 2010–11 influenza season . Morbidity and Mortality Weekly Report (MMWR). 60 . 32 . 1073–77 . August 2011 . 21849963 . https://web.archive.org/web/20170525220229/https://www.cdc.gov/mmwr/pdf/wk/mm6032.pdf . live . May 25, 2017 . Centers for Disease Control Prevention (CDC).
  188. Influenza vaccination coverage among health-care personnel: 2011–12 influenza season, United States . Morbidity and Mortality Weekly Report (MMWR). 61 . 753–57 . September 2012 . 23013720 . https://web.archive.org/web/20170624221955/https://www.cdc.gov/mmwr/PDF/wk/mm6138.pdf . live . June 24, 2017 . Centers for Disease Control Prevention (CDC).
  189. Bull AL, Bennett N, Pitcher HC, Russo PL, Richards MJ . Influenza vaccine coverage among health care workers in Victorian public hospitals . The Medical Journal of Australia . 186 . 4 . 185–86 . February 2007 . 17309419 . 10.5694/j.1326-5377.2007.tb00858.x . 25091208 .
  190. Abbasi J . The Search for a Universal Flu Vaccine Heats Up . JAMA . 322 . 20 . 1942–1944 . November 2019 . 31693060 . 10.1001/jama.2019.16816 . 207903441 .
  191. Greenfieldboyce N . New and Old Ways to Make Flu Vaccines . . November 8, 2007 . https://web.archive.org/web/20191024052018/https://www.npr.org/templates/story/story.php?storyId=16105360 . October 24, 2019 . live . October 23, 2019 . Radio broadcast .
  192. Nachbagauer R, Krammer F . Universal influenza virus vaccines and therapeutic antibodies . Clinical Microbiology and Infection . 23 . 4 . 222–228 . April 2017 . 28216325 . 5389886 . 10.1016/j.cmi.2017.02.009 .
  193. Web site: First-in-human universal flu vaccine trial begins . Balfour H . European Pharmaceutical Review . June 2, 2021 . The Phase I trial (NCT04896086) will assess the safety and immunogenicity of the experimental vaccine, FluMos-v1 . February 6, 2022 . March 29, 2022 . https://web.archive.org/web/20220329214713/https://www.europeanpharmaceuticalreview.com/news/155806/first-in-human-universal-flu-vaccine-trial-begins/ . live .
  194. Bernstein DI, Guptill J, Naficy A, Nachbagauer R, Berlanda-Scorza F, Feser J, Wilson PC, Solórzano A, Van der Wielen M, Walter EB, Albrecht RA, Buschle KN, Chen YQ, Claeys C, Dickey M, Dugan HL, Ermler ME, Freeman D, Gao M, Gast C, Guthmiller JJ, Hai R, Henry C, Lan LY, McNeal M, Palm AE, Shaw DG, Stamper CT, Sun W, Sutton V, Tepora ME, Wahid R, Wenzel H, Wohlbold TJ, Innis BL, García-Sastre A, Palese P, Krammer F . Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial . The Lancet. Infectious Diseases . 20 . 1 . 80–91 . January 2020 . 31630990 . 6928577 . 10.1016/S1473-3099(19)30393-7 . free . doi .
  195. Nachbagauer R, Feser J, Naficy A, Bernstein DI, Guptill J, Walter EB, Berlanda-Scorza F, Stadlbauer D, Wilson PC, Aydillo T, Behzadi MA, Bhavsar D, Bliss C, Capuano C, Carreño JM, Chromikova V, Claeys C, Coughlan L, Freyn AW, Gast C, Javier A, Jiang K, Mariottini C, McMahon M, McNeal M, Solórzano A, Strohmeier S, Sun W, Van der Wielen M, Innis BL, García-Sastre A, Palese P, Krammer F . A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial . Nature Medicine . 27 . 1 . 106–114 . January 2021 . 33288923 . 10.1038/s41591-020-1118-7 . free . doi .
  196. Web site: Influenza Vaccine Strategies for Broad Global Access . Path . October 2007 . September 16, 2009 . live . https://web.archive.org/web/20191014212233/https://path.org/resources/influenza-vaccine-strategies-for-broad-global-access/ . October 14, 2019 .
  197. Web site: how it's made. https://web.archive.org/web/20100705162154/http://www.ecbt.org/parents/media/pdf/howisflumade.pdf. July 5, 2010.
  198. Web site: Influenza vaccine viruses and reagents. World Health Organization (WHO). https://web.archive.org/web/20130527161247/http://www.who.int/influenza/vaccines/virus/en/. May 27, 2013.
  199. Web site: Recommendations for the production and control of influenza vaccine (inactivated). World Health Organization (WHO). May 27, 2013. live. https://web.archive.org/web/20131028160256/http://www.who.int/biologicals/publications/trs/areas/vaccines/influenza/ANNEX%203%20InfluenzaP99-134.pdf. October 28, 2013.
  200. Web site: Influenza virus growth in eggs. Racaniello V . Virology Blog. Dec 2009. live. https://web.archive.org/web/20141225163841/http://www.virology.ws/2009/12/10/influenza-virus-growth-in-eggs/. December 25, 2014 .
  201. Web site: Viral Cultivation in Chicken Embryo. Izzat F . Youtube. Apr 2012. live. https://web.archive.org/web/20150526061454/https://www.youtube.com/watch?v=766QH_qaYN8. May 26, 2015 .
  202. Web site: How Influenza (Flu) Vaccines Are Made . U.S. Centers for Disease Control and Prevention (CDC) . November 26, 2019 . https://web.archive.org/web/20191202211729/https://www.cdc.gov/flu/prevent/how-fluvaccine-made.htm . December 2, 2019 . live . December 2, 2019 .
  203. Web site: Seemann G, Kock M . 2008 . Fertile eggs – a valuable product for vaccine production . October 19, 2023 . Lohmann Breeders . en-US . November 23, 2023 . https://web.archive.org/web/20231123222125/https://lohmann-breeders.com/lohmanninfo/fertile-eggs-a-valuable-product-for-vaccine-production/ . live .
  204. Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, Pushko P, Mytle N, Rowe T, Smith G, Ross TM . Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin . Vaccine . 25 . 19 . 3871–78 . May 2007 . 17337102 . 10.1016/j.vaccine.2007.01.106 .
  205. Web site: Priming with DNA vaccine makes avian flu vaccine work better (NIH News) . October 3, 2011 . live . https://web.archive.org/web/20120927233909/http://www.nih.gov/news/health/oct2011/niaid-03.htm . September 27, 2012 .
  206. Novartis receives FDA approval for Flucelvax, the first cell-culture vaccine in US to help protect against seasonal influenza . https://web.archive.org/web/20121128072149/http://www.novartis.com/newsroom/media-releases/en/2012/1659272.shtml . live . November 28, 2012 . Novartis . November 20, 2012 .
  207. FDA approves first seasonal influenza vaccine manufactured using cell culture technology. U.S. Food and Drug Administration (FDA). https://web.archive.org/web/20130102094936/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm328982.htm. January 2, 2013.
  208. Web site: Approved Products – November 20, 2012 Approval Letter – Flucelvax. Center for Biologics Evaluation and Research . U.S. Food and Drug Administration (FDA). https://web.archive.org/web/20121203114226/https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm328684.htm. December 3, 2012.
  209. Seqirus receives FDA approval for Flucelvax Quadrivalent (Influenza Vaccine) for people four years of age and older . . May 23, 2016 . https://web.archive.org/web/20170116163927/http://www.seqirus.com/newsroom/FDA-approval-FLUCELVAX-QUADRIVALENT . January 16, 2017 . January 15, 2017 .
  210. Web site: FDA approves first flu vaccine grown in insect cells . Roos R . Center for Infectious Disease Research and Policy (CIDRAP) . October 14, 2019 . https://web.archive.org/web/20191014200136/http://www.cidrap.umn.edu/news-perspective/2013/01/fda-approves-first-flu-vaccine-grown-insect-cells . October 14, 2019 . live . October 14, 2019 .
  211. Web site: Flublok . U.S. Food and Drug Administration (FDA) . February 26, 2018 . https://web.archive.org/web/20191014200957/https://www.fda.gov/vaccines-blood-biologics/vaccines/flublok . October 14, 2019 . live . October 14, 2019 . STN 125285.
  212. Web site: Flublok Quadrivalent . U.S. Food and Drug Administration (FDA) . August 2, 2019 . https://web.archive.org/web/20191014201325/https://www.fda.gov/vaccines-blood-biologics/vaccines/flublok-quadrivalent . October 14, 2019 . live . October 14, 2019 . STN 125285.
  213. Web site: Supemtek: Pending EC decision . European Medicines Agency (EMA) . September 17, 2020 . September 21, 2020 . September 23, 2020 . https://web.archive.org/web/20200923005908/https://www.ema.europa.eu/en/medicines/human/summaries-opinion/supemtek . live . Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  214. Web site: Supemtek EPAR . European Medicines Agency (EMA) . September 15, 2020 . November 27, 2020 . January 10, 2021 . https://web.archive.org/web/20210110092717/https://www.ema.europa.eu/en/medicines/human/EPAR/supemtek . live .
  215. Web site: Supemtek Product information . Union Register of medicinal products . March 3, 2023 . March 5, 2023 . https://web.archive.org/web/20230305052137/https://ec.europa.eu/health/documents/community-register/html/h1484.htm . live .
  216. Sparrow E, Wood JG, Chadwick C, Newall AT, Torvaldsen S, Moen A, Torelli G . Global production capacity of seasonal and pandemic influenza vaccines in 2019 . Vaccine . 39 . 3 . 512–520 . January 2021 . 33341308 . 7814984 . 10.1016/j.vaccine.2020.12.018 .
  217. Jit M, Newall AT, Beutels P . Key issues for estimating the impact and cost-effectiveness of seasonal influenza vaccination strategies . Human Vaccines & Immunotherapeutics . 9 . 4 . 834–40 . April 2013 . 23357859 . 3903903 . 10.4161/hv.23637 .
  218. Postma MJ, Baltussen RP, Palache AM, Wilschut JC . Further evidence for favorable cost-effectiveness of elderly influenza vaccination . Expert Review of Pharmacoeconomics & Outcomes Research . 6 . 2 . 215–27 . April 2006 . 20528557 . 10.1586/14737167.6.2.215 . 12765724 .
  219. Newall AT, Kelly H, Harsley S, Scuffham PA . Cost effectiveness of influenza vaccination in older adults: a critical review of economic evaluations for the 50- to 64-year age group . PharmacoEconomics . 27 . 6 . 439–50 . 2009 . 19640008 . 10.2165/00019053-200927060-00001 . 20855671 . free .
  220. Newall AT, Viboud C, Wood JG . Influenza-attributable mortality in Australians aged more than 50 years: a comparison of different modelling approaches . Epidemiology and Infection . 138 . 6 . 836–42 . June 2010 . 19941685 . 10.1017/S095026880999118X . 29939376 . free .
  221. Newall AT, Dehollain JP, Creighton P, Beutels P, Wood JG . Understanding the cost-effectiveness of influenza vaccination in children: methodological choices and seasonal variability . PharmacoEconomics . 31 . 8 . 693–702 . August 2013 . 23645539 . 10.1007/s40273-013-0060-7 . 8616720 . free .
  222. Newall AT, Scuffham PA . Uncertainty and variability in influenza cost-effectiveness models . Australian and New Zealand Journal of Public Health . 35 . 6 . 576; author reply 576–77 . December 2011 . 22151168 . 10.1111/j.1753-6405.2011.00788.x . 22402257 . doi .
  223. Gatwood J, Meltzer MI, Messonnier M, Ortega-Sanchez IR, Balkrishnan R, Prosser LA . Seasonal influenza vaccination of healthy working-age adults: a review of economic evaluations . Drugs . 72 . 1 . 35–48 . January 2012 . 22191794 . 10.2165/11597310-000000000-00000 . 46305863 .
  224. Newall AT, Jit M, Beutels P . Economic evaluations of childhood influenza vaccination: a critical review . PharmacoEconomics . 30 . 8 . 647–60 . August 2012 . 22788257 . 10.2165/11599130-000000000-00000 . 38289883 . free .
  225. Newall AT, Wood JG, Oudin N, MacIntyre CR . Cost-effectiveness of pharmaceutical-based pandemic influenza mitigation strategies . Emerging Infectious Diseases . 16 . 2 . 224–30 . February 2010 . 20113551 . 2957998 . 10.3201/eid1602.090571 .
  226. Web site: Influenza Genome Sequencing Project – Overview. https://web.archive.org/web/20110627202613/http://www.niaid.nih.gov/LABSANDRESOURCES/RESOURCES/DMID/GSC/INFLUENZA/Pages/overview.aspx. June 27, 2011. National Institutes of Health – National Institute of Allergy and Infectious Diseases. May 27, 2013.
  227. Lampos V, Yom-Tov E, Pebody R, Cox IJ . 10.1007/s10618-015-0427-9 . Assessing the impact of a health intervention via user-generated Internet content . Data Mining and Knowledge Discovery . 29 . 5 . 1434–57 . 2015 . 215415165 . free . doi . August 15, 2022 . August 28, 2021 . https://web.archive.org/web/20210828124651/http://discovery.ucl.ac.uk/id/eprint/1469803/13/Assessing . live .
  228. Wagner M, Lampos V, Yom-Tov E, Pebody R, Cox IJ . Estimating the Population Impact of a New Pediatric Influenza Vaccination Program in England Using Social Media Content . Journal of Medical Internet Research . 19 . 12 . e416 . December 2017 . 29269339 . 6257312 . 10.2196/jmir.8184 . free .
  229. Web site: Acute Respiratory Infections (Update September 2009) . September 2009 . World Health Organization (WHO) . September 16, 2009 . https://web.archive.org/web/20090929200824/http://www.who.int/vaccine_research/diseases/ari/en/index1.html . September 29, 2009 .
  230. Web site: Tables on the Clinical trials of pandemic influenza prototype vaccines . July 2009 . World Health Organization (WHO). September 21, 2009 . https://web.archive.org/web/20090306161241/http://www.who.int/vaccine_research/immunogenicity/immunogenicity_table.xls . March 6, 2009 .
  231. FDA Approves Vaccines for 2009 H1N1 Influenza Virus . September 15, 2009 . October 15, 2009 . https://web.archive.org/web/20091015083833/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm182399.htm . October 15, 2009 .
  232. Web site: Keown A . FDA Approves Seqirus' Audenz as Vaccine Against Potential Flu Pandemic . BioSpace . February 4, 2020 . February 5, 2020 . February 5, 2020 . https://web.archive.org/web/20200205184348/https://www.biospace.com/article/seqirus-wins-fda-approval-of-vaccine-for-potential-flu-pandemic/ . live .
  233. Web site: Audenz . U.S. Food and Drug Administration (FDA) . January 31, 2020 . February 5, 2020 . STN: 125692 . August 6, 2020 . https://web.archive.org/web/20200806022227/https://www.fda.gov/vaccines-blood-biologics/audenz . live .
  234. Cho A, Wrammert J . Implications of broadly neutralizing antibodies in the development of a universal influenza vaccine . Current Opinion in Virology . 17 . 110–115 . April 2016 . 27031684 . 4940123 . 10.1016/j.coviro.2016.03.002 .
  235. Okuno Y, Isegawa Y, Sasao F, Ueda S . A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains . Journal of Virology . 67 . 5 . 2552–2558 . May 1993 . 7682624 . 237575 . 10.1128/JVI.67.5.2552-2558.1993 .
  236. Soema PC, Kompier R, Amorij JP, Kersten GF . Current and next generation influenza vaccines: Formulation and production strategies . European Journal of Pharmaceutics and Biopharmaceutics . 94 . 251–263 . August 2015 . 26047796 . 10.1016/j.ejpb.2015.05.023 . free . doi . 1887/43765 . free .
  237. Deng L, Cho KJ, Fiers W, Saelens X . M2e-Based Universal Influenza A Vaccines . Vaccines . 3 . 1 . 105–36 . February 2015 . 26344949 . 4494237 . 10.3390/vaccines3010105 . free . doi .
  238. Gottlieb T, Ben-Yedidia T . Epitope-based approaches to a universal influenza vaccine . Journal of Autoimmunity . 54 . 15–20 . November 2014 . 25172355 . 10.1016/j.jaut.2014.07.005 .
  239. Toussi DN, Massari P . Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands . Vaccines . 2 . 2 . 323–53 . April 2014 . 26344622 . 4494261 . 10.3390/vaccines2020323 . free . doi .
  240. Web site: Researchers Exploring Oral Flu Vaccine and Treatment Options. Sederstrom J. July 19, 2019. January 27, 2020. Drug Topics. June 8, 2020. https://web.archive.org/web/20200608032923/https://www.drugtopics.com/vaccination-and-immunization/researchers-exploring-oral-flu-vaccine-and-treatment-options. live.
  241. Jasty M, Bragdon CR, Schutzer S, Rubash H, Haire T, Harris WH . Bone ingrowth into porous coated canine total hip replacements. Quantification by backscattered scanning electron microscopy and image analysis . Scanning Microscopy . 3 . 4 . 1051–6; discussion 1056–57 . December 1989 . 2633331 . 10.1016/s1473-3099(15)00252-2 .
  242. Liebowitz D, Gottlieb K, Kolhatkar NS, Garg SJ, Asher JM, Nazareno J, Kim K, McIlwain DR, Tucker SN . Efficacy, immunogenicity, and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study . The Lancet. Infectious Diseases . 20 . 4 . 435–444 . April 2020 . 31978354 . 10.1016/S1473-3099(19)30584-5 . Elsevier . 210892802 .
  243. Web site: Flu vaccine . UK National Health Service . May 13, 2022 . August 13, 2022 . October 26, 2021 . https://web.archive.org/web/20211026210525/https://www.nhs.uk/conditions/vaccinations/flu-influenza-vaccine/ . live .
  244. Web site: Triggle N . Flu jab vital this winter along with Covid vaccine . BBC News . October 8, 2021 . August 13, 2022 . November 14, 2021 . https://web.archive.org/web/20211114150601/https://www.bbc.com/news/health-58836218 . live .
  245. Callaway E . May 16, 2022 . Flu vaccine could cut COVID risk . Nature . en . 605 . 7911 . 602 . 10.1038/d41586-022-01315-9. 35581411 . 2022Natur.605..602C . 248859545 . free .
  246. Web site: Does the Vaccine Matter? . . November 1, 2009 . December 8, 2014 . Brownlee S . live . https://web.archive.org/web/20141209000238/http://www.theatlantic.com/magazine/archive/2009/11/does-the-vaccine-matter/307723/ . December 9, 2014 .
  247. News: Rabin RC . Reassessing Flu Shots as the Season Draws Near. November 5, 2012. December 30, 2016. The New York Times. live. https://web.archive.org/web/20161110060218/http://well.blogs.nytimes.com/2012/11/05/reassessing-flu-shots-as-the-season-draws-near/. November 10, 2016. 'We have overpromoted and overhyped this vaccine,' said Michael T. Osterholm, director of the Center for Infectious Disease Research and Policy, as well as its Center of Excellence for Influenza Research and Surveillance. 'It does not protect as promoted. It's all a sales job: it's all public relations.'.
  248. http://www.influenzareport.com/ir/ai.htm Influenza Report (online book)
  249. http://195.224.162.216/equiflunet/equiflunet_vaccines.html equiflunet_vaccines
  250. Web site: UAE Equestrian & Racing Federation. https://web.archive.org/web/20050322085433/http://www.uaeequafed.ae/veterinary.htm. March 22, 2005. March 22, 2005.
  251. Web site: FEI guidelines. live. https://web.archive.org/web/20071026124033/http://www.horsesport.org/veterinary/PDFS/InflVaccGuide-E.pdf. October 26, 2007.
  252. Web site: October 10, 2023 . Vaccination of poultry against highly pathogenic avian influenza – Available vaccines and vaccination strategies . May 9, 2024 . efsa.europa.eu . en.
  253. Web site: June 3, 2024 . Making a Candidate Vaccine Virus (CVV) for a HPAI (Bird Flu) Virus . June 15, 2024 . U.S. Centers for Disease Control and Prevention (CDC) . en-us.
  254. Web site: Swine Flu Virus Turns Endemic . September 15, 2007 . https://web.archive.org/web/20090429090534/http://nationalhogfarmer.com/mag/swine_flu_virus_endemic/ . April 29, 2009 .
  255. Web site: Custom Vaccines: Swine . https://web.archive.org/web/20090430094251/http://www.livestock.novartis.com/cv_swine.html . April 30, 2009 .
  256. Karaca K, Dubovi EJ, Siger L, Robles A, Audonnet JC, Jiansheng Y, Nordgren R, Minke JM . Evaluation of the ability of canarypox-vectored equine influenza virus vaccines to induce humoral immune responses against canine influenza viruses in dogs . American Journal of Veterinary Research . 68 . 2 . 208–12 . February 2007 . 17269888 . 10.2460/ajvr.68.2.208 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Influenza vaccine".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.